

# Index

(*f*= figure; *t*= table)

- AAV. *See* Adeno-associated viral vectors
- ABCA4 gene, 294, 302
- ABCA4 retinopathy, 47–48, 50*f*
- ABCC6 gene, 95
- Abetalipoproteinemia, 324, 326
- Ablation (laser), 423. *See also* Photocoagulation
- Absolute scotoma, 391, 391*t*
- Abusive head trauma, 411, 411*f*
- ACCORD (study), 100, 105, 111
- ACCORDION (study), 100, 105
- Acetazolamide, 178, 293*f*, 347, 443
- Achromatopsia, 284, 284*t*, 456*t*
- Acute exudative polymorphous vitelliform maculopathy, 323
- Acute idiopathic maculopathy (AIM), 250, 259–260, 260*f*
- Acute macular neuroretinopathy (AMN), 250, 257–259, 259*f*
- Acute-onset postoperative endophthalmitis, 437–438, 438*t*, 439*f*
- Acute posterior multifocal placoid pigment epitheliopathy (APMPPE), 225–226, 226*f*, 250–252, 251*t*, 252*f*, 253
- Acute retinal ischemia, 160–161, 161*f*
- Acute retinal necrosis (ARN), 268, 268*f*
- Acute syphilitic posterior placoid chorioretinitis (ASPPC), 274, 275*f*
- Acute zonal occult outer retinopathy (AZOOR), 54, 250, 257, 258*f*
- Acyclovir, 269
- Adaptive optics imaging, 11*f*, 32
- Adeno-associated viral (AAV) vectors, 457, 458
- Adult-onset foveomacular vitelliform dystrophy (AOFVD), 74, 74*f*, 303, 304*f*, 306
- Adult-onset vitelliform lesions, 303, 304–305*f*
- Adult-onset vitelliform maculopathy, 74, 74*f*, 177*f*
- Advanced AMD, 66–67. *See also* Neovascular age-related macular degeneration; Nonneovascular age-related macular degeneration
- Aedes aegypti* mosquito, 279
- Afferent pupillary defect, 396, 409, 409*t*
- Aflibercept, 98
- adverse effects, 111
- diabetic macular edema treatment, 112*t*, 124–125, 126
- neovascular AMD treatment, 89*t*, 90
- polypoidal choroidal vasculopathy treatment, 85
- retinal vein occlusion treatment, 136*f*, 138*f*, 142–143*t*, 144
- route of administration, 452
- African American patients, 167, 174–175, 262
- Age
- choroidal changes, 18, 227–229, 229*f*, 242
- electroretinography testing controls for, 47
- macular changes. *See* Age-related macular degeneration
- retinal changes, 237
- retinal vein occlusion and, 135
- vitreous changes, 349
- Age-related choroidal atrophy, 227–229, 229*f*
- Age-related macular degeneration (AMD), 65–97
- about, 65–68, 67*f*
- differential diagnosis, 303–304
- epidemiology and etiology, 66, 68–69, 75
- genetics, 68–69, 304, 306
- management, 74–77, 76*t*, 86–93, 88*f*, 89*t*, 92*t*, 455, 456*t*, 457
- neovascular, 77–93. *See also* Neovascular age-related macular degeneration
- nonneovascular, 69–77. *See also* Nonneovascular age-related macular degeneration
- precautions, 335
- risk factor education, 74, 75, 75*t*
- risk factors, 68
- stages, 66–67
- studies, 65–66
- Aggressive (posterior) retinopathy of prematurity (A-ROP), 195*t*, 196–197, 199*f*
- AIDS. *See* HIV/AIDS
- AIM. *See* Acute idiopathic maculopathy
- Alagille syndrome, 316*t*, 320
- Albinism, 324–325, 325*f*
- Albinoidism, 324
- Alkyl nitrites (“poppers”), 340, 340*t*, 341*f*
- Alphavirus*, 281
- $\alpha$ -Mannosidosis, 316*t*
- Alport syndrome, 306, 319*t*
- Alström syndrome, 319*t*, 320
- Aluminum, 404*f*, 406
- Amacrine cells, 13, 14*f*
- Amalric triangles, 225
- Amblyopia, 209–210, 360
- AMD. *See* Age-related macular degeneration
- Amelogenesis imperfecta, 322
- American Academy of Ophthalmology, 162
- American Diabetes Association, 100
- American Heart Association, 160, 162
- Amikacin, 342, 438, 438*t*
- Amino acid disorders, 329
- Aminoglycosides, 342, 408
- AMN. *See* Acute macular neuroretinopathy
- Amniotic fluid embolism, 192
- Amphotericin B, 272, 273*f*
- Amsler grid testing, 76, 77
- Amyloidosis, 366–367, 366*f*
- Anaphylaxis, 39
- ANCHOR (study), 65, 88–89, 88*f*, 89*t*
- Ancylostoma caninum*, 279
- Anemia, 108
- Anesthesia, 421, 452–453
- Aneurysmal telangiectasia, 180–181, 181–183*f*
- Aneurysms
- macroaneurysms, 132–133, 165–166, 166*f*, 176, 190
- microaneurysms, 108–109, 109*f*, 178, 179*f*, 188, 239
- Angiogenesis, 87, 193. *See also* Antiangiogenic therapies

- Angiography  
 fluorescein, 32–38. *See also* Fluorescein angiography  
 indocyanine green, 23, 38–39, 38–39*f*  
 optical coherence tomographic angiography, 28–29, 30*f*  
 scanning laser ophthalmoscopy and, 25–26, 25*f*
- Angioid streaks, 17, 95–96, 95*f*, 171, 174, 321
- Angiokeratoma corporis diffusum, 328–329
- Annular gap, 5–7
- Anomaloscope, 57
- Anomalous foveal anatomy, 210, 212*f*
- Anomalous trichromatism, 283–284
- Anterior capsular phimosis, 129
- Anterior chamber, 41, 119, 161
- Anterior ciliary arteries, 222
- Anterior cortical gel, 5
- Anterior hyaloid, 6*f*
- Anterior ischemic optic neuropathy, 134
- Anterior persistent fetal vasculature, 360
- Anterior segment  
 blunt trauma sequelae, 397  
 neovascularization  
   in central retinal artery occlusion, 162  
   in central retinal vein occlusion, 137, 148, 149, 151–152  
   in ocular ischemic syndrome, 152, 152*f*, 154  
 surgery complication management, 437–445, 438*t*, 439–440*f*, 441*t*
- Antiangiogenic therapies, 87–93  
 about, 87  
 adverse effects, 81, 91, 111  
 alternatives, 127  
 choroidal neovascularization treatment, 240, 241*f*  
 clinical approaches, 87  
 Coats disease treatment, 179  
 combination therapies, 93  
 diabetic macular edema treatment, 116*f*, 122, 124–126, 125*f*  
 diabetic retinopathy treatment, 111, 115–117, 116*f*, 119, 120  
 imaging findings following, 80*f*  
 macular telangiectasia treatment, 180  
 pathologic myopia treatment, 96–97  
 radiation retinopathy treatment, 189  
 retinal venous occlusion treatment, 136*f*, 138–139, 138*f*, 141–143*t*, 144, 149  
 retinopathy of prematurity treatment, 207–209  
 specific agents, 88–91, 88*f*, 89*t*, 92
- Antibiotics. *See also specific antibiotics*  
 for globe injuries, 407–408  
 microvasculopathy complications, 342  
 postoperative endophthalmitis treatment, 438–441, 438*t*, 439–440*f*
- Anticoagulants, 365
- Antioxidants, 75, 76*t*
- Anti-VEGF therapy. *See* Antiangiogenic therapies
- AOFVD. *See* Adult-onset foveomacular vitelliform dystrophy
- APC gene, 320
- Aphakia, 381
- APMPPE. *See* Acute posterior multifocal placoid pigment epitheliopathy
- Apolipoprotein B, 326
- Appositional choroidal detachment (“kissing choroidals”), 40*f*, 443
- Appositional suprachoroidal hemorrhage, 443, 445
- ARB. *See* Autosomal recessive bestrophinopathy
- Arden index (ratio), 54
- Area centralis, 7, 7*f*, 8*t*
- Area of Martegiani, 6*f*, 7, 349
- AREDS (study), 66, 70, 75, 75*t*
- AREDS2 (study), 66, 75–76, 76*t*
- Arginine, 300
- Argyrosis, ocular, 347
- ARMS2 gene, 68
- ARN. *See* Acute retinal necrosis
- A-ROP. *See* Aggressive retinopathy of prematurity
- Arrestin, 287
- Arterial occlusive disease, 154–164  
 acute retinal ischemia and, 160–161, 161*f*  
 branch, 155–156, 156–157*f*, 157*t*, 172*f*, 176  
 central, 158–162. *See also* Central retinal artery occlusion  
 cilioretinal artery occlusion, 162, 163*f*  
 cotton-wool spots, 154, 155*f*, 155*t*, 157*f*  
 drug-induced, 342, 343  
 etiology, 155, 157*t*, 159–160  
 ophthalmic artery occlusion, 162–163, 164*f*  
 paracentral acute middle maculopathy, 164, 165*f*, 259, 259*f*  
 radiation retinopathy complication, 188
- Arteriohepatic dysplasia, 316*t*, 320
- Arteriosclerotic retinopathy, 132
- Arteritic ischemic optic neuropathy, 222, 222*f*
- Arthro-ophthalmopathy, 316*t*
- Artifacts, 29
- Artificial intelligence, 104
- A-scans, 26
- Ascorbate, 7
- Asian patients, 334, 335*f*, 336
- Aspergillus* endophthalmitis, 272, 272*f*
- Aspirin, 107
- ASPPC. *See* Acute syphilitic posterior placoid chorioretinitis
- Asteroid hyalosis, 364–365, 364*f*, 366
- Atherosclerosis, 153
- ATOH7* gene, 360
- Atrophic creep, 96
- Atrophic retinal holes, 210*f*, 371, 372–373*f*, 376, 378*f*, 379*t*, 380
- Atrophy. *See also* Geographic atrophy  
 of choriocapillaris, 289  
 choroidal, 226, 227–229, 229*f*, 242–243, 243*f*  
 of gyrate, 299–300, 300*f*  
 macular, 292*f*, 295, 296*f*, 302, 302*f*, 306, 307, 307*f*  
 optic atrophy, 51, 188  
 of retinal pigment epithelium, 66, 70, 71–73, 72*f*, 119*f*, 226, 303, 331*f*, 425
- Atropine, 236
- Attenuated mucopolysaccharidosis, 316*t*
- Atypical hemolytic uremia syndromes, 306
- Atypical macular dystrophies, 308–309
- Aurora borealis effect, 265
- Autoimmune retinopathy, 323
- Autoimmunity  
 central serous retinopathy association, 217

- inflammatory vasculitis, 261–262, 261*t*, 262*f*  
 intraocular lymphoma, 264–267, 265–266*f*  
 lupus vasculitis, 262, 262*f*  
 retinopathy, 323  
 sympathetic ophthalmia, 263  
 Vogt-Koyanagi-Harada disease, 263, 264*f*
- Autoinfarction, 171, 173*f*  
 Autosomal dominant drusen, 304  
 Autosomal dominant inherited retinal diseases, 457  
 Autosomal recessive bestrophinopathy (ARB), 54, 303  
 Avacincapad pegol, 98  
 a-waves  
   electroretinography, 45–47, 46*f*, 52, 285  
   in macular dystrophies, 313  
   in rod-cone dystrophies, 291
- Azathioprine, 261  
 AZOOR. *See* Acute zonal occult outer retinopathy
- Bacillus cereus* endophthalmitis, 408  
 Background diabetic retinopathy, 101  
 Bacterial endophthalmitis, 270–271, 271*f*, 408  
 Bardet-Biedl syndrome, 316*t*, 318–319, 318*f*, 320  
*Bartonella henselae*, 274, 276*f*  
 Bartonellosis, 274, 276*f*  
 Basal laminar (cuticular) drusen, 304–305, 306*f*  
 Basilar laminar deposits, 67, 67*f*, 69–70  
 Basilar linear deposits, 67, 67*f*, 70  
 Batten disease (neuronal ceroid lipofuscinoses), 316*t*,  
   317*t*, 325–326, 326*f*  
*Baylisascaris procyonis*, 279  
 BCM. *See* Blue-cone monochromatism  
 BDUMP. *See* Bilateral diffuse uveal melanocytic  
   proliferation  
 Bear tracks, 320, 321*f*  
 “Beaten-bronze,” 301*f*  
 BEAT-ROP (study), 206*t*, 207–208, 209  
 Behçet disease, 261, 261*t*  
 Berger space, 5, 6*f*  
 Bergmeister papilla, 358  
 Best disease, 54, 55*f*, 302–303, 302*f*  
*BEST1* gene, 54, 303, 308  
 Bestrophin, 54, 303  
 Best vitelliform dystrophy, 54, 55*f*, 302–303, 302*f*  
 Bevacizumab  
   adverse effects, 91  
   choroidal neovascularization treatment, 241*f*  
   diabetic macular edema treatment, 112*t*, 124–125  
   neovascular AMD treatment, 90–91, 92*t*  
   retinal vein occlusion treatment, 142–143*t*, 144, 144*f*  
   retinopathy of prematurity treatment, 206*t*, 207–208  
   route of administration, 452
- Bietti crystalline dystrophy, 300, 316*t*, 329, 345*f*  
 Bilateral diffuse uveal melanocytic proliferation  
   (BDUMP), 233–234, 234*f*, 323
- Binocular indirect ophthalmoscopes/ophthalmoscopy, 22  
 Bipolar cells (BPCs), 13, 14*f*, 45
- Birdshot chorioretinopathy, 39, 53, 251*t*, 255–256, 255*f*  
 Birdshot uveitis, 265, 266  
 Birdshot uveitis-like fundus appearance, 265–266, 266*f*  
 Bisretinoids, 29–30  
 Black “sunburst” lesions, 168  
 Bleb-associated endophthalmitis, 440–441, 440*f*  
 Blebitis, 440
- Blind loop syndrome, 326  
 Blindness  
   age-related macular degeneration progression to, 93  
   drug-induced, 343  
   persistent fetal vasculature as cause of, 360
- Bloch-Sulzberger syndrome, 317*t*, 320  
 Blocked fluorescence, 35  
 Blood-brain barrier, 14  
 Blood hyperviscosity, 150  
 Blood-ocular barrier, 33  
 Blood-retina barrier, 33, 35–36, 36*f*, 121–122, 121*f*, 123  
 Blue-cone monochromatism (BCM), 49*f*, 284, 285  
 Blue cones, 57  
 Blue-yellow color deficiency, 57  
 Blunt trauma, 376, 397–401. *See also* Closed-globe  
   injuries
- Bone spicules, 292*f*  
*Borrelia burgdorferi*, 278  
 “Boxcarring” of blood flow, 157*f*  
 BPCs. *See* Bipolar cells  
 Bradyopsia, 53  
 BRAMD (study), 92*t*  
 Branch retinal artery occlusion (BRAO), 155–156,  
   156–157*f*, 157*t*, 172*f*, 176  
 Branch retinal vein occlusion (BRVO), 134–148  
   about, 134, 145  
   clinical findings, 134, 135–136*f*  
   complications, 132–133, 137–138, 139*f*  
   cystoid macular edema etiology, 176  
   differential diagnosis, 179  
   electroretinography findings, 47  
   management  
     pharmacologic, 138–139, 140–143*t*, 144–145, 144*f*,  
       146  
     surgical, 146–148, 147*f*  
   pathogenesis, 134–135  
   prognosis, 145–146, 146*f*  
   risk factors, 135–137
- BRAO. *See* Branch retinal artery occlusion  
 BRAVO (study), 141*t*, 144, 145  
 “Bridge arch-shaped” serous pigment epithelial  
   detachment (PED), 81
- Brolicizumab, 342  
 Bruch membrane  
   age-related changes, 67, 67*f*, 69–70, 77, 78*f*  
   anatomy, 16*f*, 17  
   angioid streaks and, 95  
   degeneration of, 17  
   myopia and, 239, 240*f*, 243, 246, 246*f*  
   rupture of, 424  
   tears, 398
- Brunette fundi, 306*f*  
 BRVO. *See* Branch retinal vein occlusion  
 B-scan optical coherence tomography, 83*f*  
 B-scans (ultrasonography), 26, 27*f*, 39–41, 40–41*f*, 397  
 “Bubbly” appearance, 389, 390–391  
 Bullous retinoschisis, 310, 312*f*, 390, 390*f*  
 Bull’s-eye maculopathy, 318, 326, 326*f*, 334, 336*f*  
 Bull’s-eye pattern  
   in acute idiopathic maculopathy, 260  
   in Bardet-Biedl syndrome, 318  
   in cone dystrophies, 295, 296*f*  
   in Stargardt disease, 301*f*

- Bull's-eye rash, 278  
 Bupropion, 347  
 Burns, 412, 424  
 Butterfly-type pattern dystrophy, 306, 308f  
 BUTTERFLEYE (study), 208  
 BVOS (study), 140t  
 b-waves, 45–47, 46f, 53, 285, 291, 313
- CACNA1F gene, 286  
 Calcific drusen, 73  
 Calcific emboli, 156  
 Cancer, 322–323, 323f, 389f  
 Cancer-associated retinopathy (CAR), 322–323, 323f  
*Candida* endophthalmitis, 265f, 272, 273f, 408  
 Canthaxanthine, 346  
 Capillary plexus, 13–14  
 CAR. *See* Cancer-associated retinopathy  
 Carbogen therapy, 161  
 Carbonic anhydrase inhibitors, 174, 291  
 Cardiac myxoma, 156  
 Cardiovascular disease. *See* Arterial occlusive disease; Hypertension; Ocular ischemic syndrome; Retinal venous occlusion  
 Carotid-cavernous fistulas, 226, 228f  
 Carotid occlusive disease, 108, 152–153f, 152–154  
 Cataractous lens, 41f  
 Cataracts, 47, 212f, 291, 296  
 Cataract surgery  
   age-related macular degeneration progression affected by, 76  
   complications, 441–442, 441t  
   cystoid macular edema etiology, 176, 178  
   diabetic macular edema treatment and, 124  
   diabetic patient precautions, 128–129  
   photic retinopathy after, 413  
   retinal detachment after, 381  
 Cat-scratch disease, 274, 275f  
 CATT (study), 66, 91, 92t  
 Cavernous hemangioma, 186–187, 187f  
 Cefazidime, 438, 438t  
 Cellophane maculopathy, 353  
 Center-involved diabetic macular edema, 101, 112t, 122, 123f, 126  
 Central areolar choroidal dystrophy, 308, 310f  
 Central blindness, 93  
 Central nervous system  
   Behçet disease involvement of, 261  
   incontinentia pigmenti and retinal degeneration, 321  
   metabolic diseases and  
     abetalipoproteinemia, 324, 326  
     Fabry disease, 328–329  
     mucopolysaccharidoses, 316t, 319t, 327  
     neuronal ceroid lipofuscinoses, 317t, 325–326, 326f  
     Tay-Sachs disease, 328, 328–329f  
     Zellweger spectrum disorders, 317t, 326–327, 327f  
   primary vitreoretinal lymphoma involvement of, 264, 266  
 Central retinal artery, 13, 15f  
 Central retinal artery occlusion (CRAO)  
   about, 157–159f, 158–160, 162  
   causes, 15f, 188, 343  
   imaging techniques, 53  
   management, 160–162, 161f
- Central retinal vein occlusion (CRVO)  
   about, 134–137, 148  
   clinical findings, 134, 137f, 149  
   complications, 132–133, 137–138, 139f  
   cystoid macular edema etiology, 176  
   differential diagnosis, 134, 150–151, 153  
   drug-induced, 343  
   evaluation, 53, 151  
   management  
     follow-up evaluations, 151  
     pharmacologic, 138–139, 140–143t, 144–145, 144f, 151  
     surgical, 151–152  
   pathogenesis, 134–135  
   risk factors, 135–137  
   sickle cell retinopathy and, 168  
   types, 148–149, 149–150f
- Central serous chorioretinopathy (CSC)  
   clinical variations, 216–217, 216f  
   differential diagnosis, 73–74, 86, 218–221  
   drug-induced, 338–339  
   epidemiology, 215–216  
   imaging techniques, 32, 39, 217–218, 217–221f  
   management, 221  
   systemic associations, 217
- Central serous retinopathy (CRS), 215  
 Ceramide trihexoside, 328  
 Cerebral vasculitis, 250  
 Cerebrohepatorenal syndrome (Zellweger spectrum disorders), 317t, 326–327, 327f  
 Ceroid, 325  
 CFH gene, 68  
 Chalcosis, 407  
 Charcot-Marie-Tooth disease, 316t  
 Chédiak-Higashi syndrome, 324  
 Chemical-induced diabetes, 100  
 Chemotherapy, 265, 269f  
 Cherry-red spot  
   central retinal artery occlusion finding, 158, 158f, 161f  
   drug-induced, 343  
   lysosomal metabolic disorder finding, 328, 328f  
   ophthalmic artery occlusion finding, 163  
   trauma-related, 398
- Chikungunya virus retinitis, 281  
 Children. *See also specific congenital disorders*  
   Coats disease, 178–179, 179f  
   developmental abnormalities, 358–361  
   electrophysiologic testing modalities for, 53, 56  
   trauma-related injuries, 377–379, 411, 411f
- Chloroquine, 333–335  
 Chloroquine derivatives, 333–337, 334–336f  
 Chlorpromazine, 337  
 CHM gene, 299  
 Cholesterol emboli, 156, 157f, 159  
 Cholesterosis, 366  
 Choriocapillaris  
   about, 225–226, 226–227f  
   age-related changes, 67, 67f, 77, 78f  
   anatomy, 14, 17, 18, 18f  
   atrophy of, 289  
   hypertensive choroidopathy and, 133–134  
   imaging techniques, 30f  
 Chorioretinal disruption, 398, 401, 401f

- Chorioretinal edema, 425  
 Chorioretinal folds, 230, 230f, 231t  
 Chorioretinal scars, 275  
 Chorioretinitis sclopetaria, 398, 401, 401f  
 Chorioretinopathy  
   birdshot, 39, 53, 251t, 255–256, 255f  
   central serous chorioretinopathy, 215–221. *See also*  
     Central serous chorioretinopathy  
   diagnostic imaging, 32, 36, 39  
   management, 426  
 Choroid  
   anatomy, 14, 17–19, 18f, 222  
   effusions, 40f, 41, 347  
   imaging techniques, 25, 33, 33f, 34–35, 39, 39f  
   myopia and, 239–243, 240–244f  
   thinning of, 240–242, 242f  
 Choroidal detachments  
   differential diagnosis, 382  
   imaging techniques, 40  
   photocoagulation-related, 118, 424, 425, 425f  
 Choroidal dystrophies  
   Bietti crystalline dystrophy, 289, 300, 316f  
   central areolar, 308, 310f  
   choroideremia, 289, 297–299, 299f  
   classification, 289  
   diagnostic considerations, 289–290  
   genetics, 290  
   gyrate atrophy, 299–300, 300f  
   management, 290–291  
   terminology, 288  
 Choroidal folds, 230, 230f, 231t  
 Choroidal granulomas, 273f  
 Choroidal hemangiomas, 231, 232f  
 Choroidal inflammatory disease, 249–281  
   about, 249  
   autoimmune conditions, 261–263, 261t, 262f, 263f  
   infectious, 272–281  
   white dot syndromes, 250–257, 251t, 253f, 255–257f  
 Choroidal melanomas, 425  
 Choroidal neovascularization (CNV)  
   about, 65–67, 93, 97t  
   acute posterior multifocal placoid pigment  
     epitheliopathy association, 252  
   Best disease association, 302  
   causes  
     age-related macular degeneration, 77–93.  
       *See also* Neovascular age-related macular  
       degeneration  
     angioid streaks, 95–96, 95f  
     idiopathic and miscellaneous, 97, 97t  
     laser treatments, 127  
     miscellaneous, 97  
     ocular histoplasmosis syndrome, 93–95, 94f  
     pathologic myopia, 96–97, 96f  
   choroidal folds association, 230, 231t  
   choroidal rupture complication, 399, 400f  
   classification, 77–78, 78f  
   differential diagnosis, 218, 303  
   imaging techniques, 30, 31f, 36, 37f, 39, 39f  
   macular dystrophy association, 306, 307f  
   management, 86–93, 88f, 89t, 92t, 422, 426  
   multifocal choroiditis in, 257, 257f  
   myopic, 239–240, 240–244f  
     ocular histoplasmosis syndrome and, 93–95, 94f  
     pathologic myopia and, 96–97, 96f, 239–240,  
       241–244f  
 Choroidal nevi, 25  
 Choroidal noninflammatory disease, 215–234  
   age-related choroidal atrophy, 227–229, 229f  
   bilateral diffuse uveal melanocytic proliferation,  
     233–234, 234f, 323  
   central serous chorioretinopathy, 215–221. *See also*  
     Central serous chorioretinopathy  
   choroidal folds, 230, 230f, 231t  
   choroidal hemangiomas, 231, 232f  
   choroidal perfusion abnormalities, 222–227  
   uveal effusion syndrome, 231–232, 233f  
 Choroidal perfusion abnormalities, 222–227  
   arteritic disease, 222, 222–223f  
   choriocapillaris blood flow abnormalities, 225–226,  
     226–227f  
   increased venous pressure, 226–227, 228f  
   nonarteritic disease, 222–225, 224–225f  
 Choroidal polyps, 34f  
 Choroidal rupture, 95–96, 397, 398–399, 399–400f  
 Choroidal tumors, 382  
 Choroideremia, 289, 297–299, 299f, 456t  
 Choroidopathy, 133–134  
 Choroid photocoagulation-related lesions, 425  
 Chronic progressive external ophthalmoplegia (CPEO),  
   330, 330f  
 CHRPE. *See* Congenital hypertrophy of the retinal  
   pigment epithelium  
 Cicatricial retinal detachment, 321  
 Cigarette smoking, 68, 135  
 Ciliary arteries, 222  
 Ciliary body, 7, 9f, 15, 41  
 Cilioretinal artery, 13, 15f, 158, 158f  
 Cilioretinal artery occlusion, 162, 163f  
 Cilium, 11, 12f  
 Circle of Zinn-Haller, 246  
 11-*cis*-retinaldehyde, 17  
 11-*cis*-retinol dehydrogenase, 286  
 Cisterns, in vitreous, 7  
 CLARITY (study), 100  
 Classic choroidal neovascularization (CNV), 77, 79  
 Clindamycin, 276, 438t  
 Clinically significant diabetic macular edema (CSME),  
   101, 122, 127  
 Clinically significant retinopathy of prematurity  
   (CSRP), 203  
 Clofazimine, 337, 340t  
 Cloquet canal, 6f, 7, 358, 359f  
 Closed-globe injuries, 397–401  
   choroidal rupture, 95–96, 397, 398–399, 399–400f  
   classification, 395  
   commotio retinae, 397, 398, 398f  
   evaluations, 396–397, 396t  
   posttraumatic macular hole, 399–400  
   prognostication, 409–410, 409t  
   sequelae, 397–398  
   traumatic chorioretinal disruption, 401, 401f  
   vitreous hemorrhage and, 397, 400–401  
 CME. *See* Cystoid macular edema  
 CMV. *See* Cytomegalovirus retinitis  
 CNV. *See* Choroidal neovascularization

- Coats disease, 178–179, 179f, 180  
 Coats reaction, 179, 185, 291  
 Cobblestone degeneration, 374–375, 375f  
 Cockayne syndrome, 319t  
 COL2A1 gene, 361  
 Collagen fibers, in vitreous, 7  
 Collagen vascular disease, 192  
 Collateral vessels, 137–138, 139f  
 Colloidal silver, 347  
 Coloboma-like excavated macular defect, 309, 311f  
 Color vision  
   about, 57  
   dysfunctions, 118, 283–285, 284t, 286f, 347  
   testing of, 57–59, 58–59f  
 “Comet” sign, 95, 95f  
 Comma sign, 171  
 Commotio retinae, 397, 398, 398f  
 Complete achromatopsia, 284–285  
 Complete congenital stationary night blindness (CSNB), 49f, 286, 286f  
 Complex retinal detachment, 450  
 Computed tomography (CT), 397  
 COMRADE C (study), 141t, 145  
 Cone dystrophies, 47–48, 48f, 52–53  
 Cone-rod dystrophies, 47–48, 295–296, 296f, 322  
 Cone(s)  
   age-related changes, 67  
   anatomy, 11–13, 12f  
   color vision and, 57  
   density and distribution of, 9–11  
   electroretinography testing, 45–51, 46f, 48–49f  
   psychophysical evaluations, 61  
   shedding by, 17  
 Confluent drusen, 69f, 70  
 Congenital color deficiency, 283–285, 284t, 286f  
 Congenital hypertrophy of the retinal pigment epithelium (CHRPE), 321f  
 Congenital nystagmus, 284  
 Congenital rubella syndrome, 319t  
 Congenital stationary night blindness (CSNB), 49f, 52, 285–286, 286f, 319  
 Congenital toxoplasmosis, 275  
 Conjunctival filtering blebs, 440, 440f  
 Contact B-scan ultrasonography, 39–40, 40f  
 Contact lenses, 23, 421, 422t, 441–442, 441t  
 Contrast sensitivity (CS), 57, 59–60, 60f, 118  
 Contusion trauma, 376–377, 395  
 COPERNICUS, 142t, 144  
 Copper, 406, 407  
 Corkscrew vessels, 228f  
 Corneal burns, 424  
 Corneal lacerations, 403  
 Cornea verticillata, 329, 334  
 Corticosteroids  
   acute posterior multifocal placoid pigment epitheliopathy treatment, 250–252  
   adverse effects, 145, 217, 222, 268, 339, 340t  
   cystoid macular edema treatment, 178, 443  
   diabetic macular edema treatment, 111, 126–127  
   diabetic retinopathy treatment, 117  
   giant cell arteritis treatment, 160  
   implants, 126, 145  
   precautions, 265  
   progressive outer retinal necrosis syndrome treatment, 268  
   pseudophakic cystoid macular edema treatment, 177f, 178  
   radiation retinopathy treatment, 189  
   retinal venous occlusion treatment, 139, 140–141t, 145  
   route of administration, 452  
   Susac syndrome treatment, 176  
   toxoplasmic retinochoroiditis treatment, 276  
 Cotton-wool spots  
   amyloidosis finding, 367  
   arterial occlusive disease findings, 154, 155f, 155t, 157f  
   causes of, 155t  
   diabetic retinopathy finding, 108, 114f, 154  
   differential diagnosis, 267  
   drug-induced, 342  
   hypertensive retinopathy findings, 132, 132–133f  
   Purtscher and Purtscher-like retinopathy finding, 190, 191f  
   radiation retinopathy finding, 188, 188f  
   retinal venous occlusion finding, 134, 135f  
   systemic lupus erythematosus finding, 262  
   trauma-related, 411  
 Coxsackievirus infection, 260  
 CPEO. *See* Chronic progressive external ophthalmoplegia  
 CRAO. *See* Central retinal artery occlusion  
 CRAVE (study), 142t  
 CRB1-associated RP1, 179  
 CRB1 gene, 292f  
 CRISPR/Cas9-based technology, 458  
 Crohn disease, 175f  
 CRS. *See* Central serous retinopathy  
 CRUISE (study), 142t, 144  
 CRVO. *See* Central retinal vein occlusion  
 Cryopexy, 427, 448  
 CRYO-ROP (study), 194, 204, 205t  
 Cryotherapy  
   about, 426–427  
   cryopexy technique, 427, 448  
   hemangioma treatment, 231  
   retinal break treatment, 379  
   retinal cavernous hemangioma treatment, 187  
   retinopathy of prematurity treatment, 205t, 207  
   von Hippel–Lindau syndrome treatment, 184–185  
 Cryotherapy for Retinopathy of Prematurity Cooperative Group, 194  
 Crystalline retinopathy, 329, 344–346, 345–346f, 346t  
 CS. *See* Contrast sensitivity  
 CSC. *See* Central serous chorioretinopathy  
 C-scans, 26  
 CSME. *See* Clinically significant diabetic macular edema  
 CSNB. *See* Congenital stationary night blindness  
 CSROP. *See* Clinically significant retinopathy of prematurity  
 CT. *See* Computed tomography  
 CTNNA1 gene, 308  
 Culex mosquitoes, 279  
 Cushing syndrome, 217  
 Cuticular (basal laminar) drusen, 304–305, 306f  
 CVOS (study), 140t, 149f

- Cyclodialysis clefts, 41  
 Cyclosporine, 261  
 CYP4V2 gene, 289, 300  
 Cysteamine, 329  
 Cystic retinal tufts, 371–372, 373f  
 Cystinosis, 329  
 Cystoid macular edema (CME)  
   about, 176, 177f  
   age-related macular degeneration finding, 77, 79  
   birdshot chorioretinopathy association, 255–256  
   cytomegalovirus retinitis association, 268  
   differential diagnosis, 178  
   drug-induced, 343  
   etiology, 146, 146f, 176–178  
   imaging techniques, 36f, 176  
   macular telangiectasia association, 180  
   management, 144, 144f, 178, 443, 443f  
   pseudophakic, 176–178, 177f  
   in retinal dystrophies, 290, 291, 293f  
   toxocariasis association, 277  
 Cysts, 41, 375–376, 382, 385f, 392  
 Cytomegalovirus (CMV) retinitis, 267–268, 267f, 269, 270t
- Dalen-Fuchs nodules, 263  
 Dark adaptation responses  
   in electro-oculography, 53–54, 54–55f  
   in electroretinography, 44t, 45, 46f, 47, 48–50f, 52–53, 52f  
   psychophysical evaluations, 61  
 Dark adaptometry, 61  
 “Dark-choroid,” 300  
 Day blindness, 295  
 DCCT (study), 100, 104–105, 106t  
 Deafness, 226  
 Deep capillary plexus, 13–14, 30f  
 Deferoxamine (desferrioxamine), 337–338, 339f, 340t, 344  
 Delamination, 437  
 Demarcation lines, 378, 381, 387, 387f, 392  
 Demyelinating optic neuritis, visual evoked potentials  
   in, 55  
 Dental diseases, 322  
 Dentate processes, 9, 9f  
 DERBY (study), 97–98  
 Dermatologic diseases, 320–322, 322f  
 Descemet membrane, 407  
 Desferrioxamine (desferrioxamine), 337–338, 339f, 340t, 344  
 Deutan red-green color deficiency, 57, 59  
 Developmental abnormalities, 358–361  
   persistent fetal vasculature, 360  
   prepapillary vascular loops, 358, 359f  
   tunica vasculosa lentis, 358, 359f  
 Dexamethasone, 141t, 145, 276, 438, 453  
 Dexamethasone implants, 126, 145  
 DHA. *See* Docosahexaenoic acid  
 Diabetes mellitus  
   asteroid hyalosis association, 364  
   cataract surgery precautions, 128–129  
   choroidal perfusion abnormalities association, 226  
   classification, 100  
   examination recommendations, 103–104, 104–105t  
   hypertension and, 132, 133, 161  
   ocular ischemic syndrome association, 153f  
   photocoagulation precautions, 425  
   retinal venous occlusion risk factor, 135, 136  
   terminology, 100  
 Diabetic macular edema (DME), 121–128  
   about, 121–122, 121f  
   classification, 101, 122–123, 122–123f  
   defined, 101  
   etiology, 111  
   evaluations, 59  
   management  
     about, 123–124, 437  
     nonpharmacologic, 127–128  
     pharmacologic, 111, 116f, 124–126, 125f  
     photocoagulation for, 422  
     subthreshold laser delivery systems for, 424  
     systemic management, 108  
   studies, 100, 112f  
   vision loss and, 108, 109–110  
 Diabetic nephropathy, 108  
 Diabetic papillopathy, 120, 134  
 Diabetic retinopathy, 99–129  
   about, 99  
   classification, 100–101  
   cotton-wool spot finding, 108, 114f, 154  
   cystoid macular edema etiology, 176  
   diabetic macular edema, 121–128. *See also* Diabetic macular edema  
   differential diagnosis, 179, 188  
   epidemiology, 101–102  
   examination recommendations, 103–104, 104–105t  
   hypertension and, 132–133  
   management, 104–108, 106–107t, 435–437, 436f  
   nonproliferative, 101, 108–111. *See also* Nonproliferative diabetic retinopathy  
   pathogenesis, 102, 103f  
   proliferative, 101, 111–120. *See also* Proliferative diabetic retinopathy  
   studies, 100  
   terminology, 100–101  
   vision loss clinical signs, 108  
 Diabetic Retinopathy Clinical Research Network, 116.  
   *See also* DRCR Retina Network  
 Dialyses, 376, 377, 379t, 382, 385f  
 Dichromacy, 284, 284t  
 Dichromatism, 284, 284t  
 Didanosine, 338, 340t  
 Dideoxyinosine, 338, 340t  
 Diet, retinopathy of prematurity and, 204  
 Diffuse macular edema, 123  
 Diffuse unilateral subacute neuroretinitis (DUSN), 279, 280f  
 Digital Diagnostics (IDx-DR), 104  
 Digitalis, 347  
 Diplopia, 425  
 Direct ophthalmoscope/ophthalmoscopy, 22–23.  
   *See also* Ophthalmoscopy  
 Disseminated intravascular coagulation, 223  
 DME. *See* Diabetic macular edema  
 Docetaxel, 343  
 Docosahexaenoic acid (DHA), 75  
 Dominant (familial) exudative vitreoretinopathy (FEVR), 179

- Dot form, 216, 216f  
 Doughnut pattern, 347  
 Doxycycline, 279  
 Doyme honeycomb dystrophy, 305  
 DRCR Retina Network (studies), 109, 111, 112–113t, 115–116, 116f, 117, 120, 124, 125f, 126, 128  
 DRS (study), 100, 107t, 117–118, 118f  
 Drug-induced diabetes, 100  
 Drusen  
   age-related choroidal degeneration finding, 229f  
   age-related macular degeneration finding, 67, 67f, 69–71, 69f, 71f, 75  
   categorization of, 70  
   choroidal neovascularization, 39  
   confluent, 69f, 70  
   hard, 70  
   imaging techniques, 24f, 27f, 34f, 39, 40, 69f, 70–72  
   macular dystrophy finding, 303–306, 305–307f, 309, 311f  
   pseudoxanthoma elasticum finding, 95  
   soft, 229f, 303  
 Drusenoid pigment epithelial detachment (PED), 70, 303, 305f  
 DRVS (study), 100, 120  
 “Dry” age-related macular degeneration. *See* Nonneovascular age-related macular degeneration  
 Duchenne muscular dystrophy, 319  
 Dural arteriovenous malformations, 226  
 DUSN. *See* Diffuse unilateral subacute neuroretinitis  
 “Dustlike” pigment mottling, 306, 308f  
 Dwarfism, 361  
 Dyschromatopsias, 283–285  
 Dystrophic lipidization, 73  
 Dystrophies. *See also* Cone dystrophies; Macular dystrophies; Rod–cone dystrophies  
   choroidal, 297–300, 299–300f, 316t. *See also* Choroidal dystrophies  
   cone–rod, 322  
   macular, 300–310. *See also* Macular dystrophies  
   retinal, 288–297, 310–313. *See also* Retinal dystrophies  
   rod–cone, 318. *See also* Retinitis pigmentosa  
 Dystrophin, 319  
 Eales disease, 176, 272  
 Early-onset “drusenoid” macular dystrophies, 303–306, 305–306f  
 Early Treatment of Retinopathy of Prematurity (ETROP), 194, 204, 205t, 210  
 Ebola virus (EBOV) panuveitis, 281  
 Eclampsia, 223, 224f  
 Eclipse retinopathy, 412–413, 413f  
 EDI-OCT. *See* Enhanced depth imaging optical coherence tomography  
 EFEMP1 gene, 305  
 Egg yolk–like (vitelliform) macular lesion, 302–303, 302f  
 Ehlers–Danlos syndrome, 95  
 Eicosapentaenoic acid (EPA), 75  
 Electrical injuries, 400  
 Electro-oculography/electro-oculogram (EOG), 44t, 53–55, 54–55f  
 Electrophysiologic testing, 43–56  
   about, 43–44, 44t, 56–57  
   electro-oculography, 53–55, 54–55f  
   electroretinography, 44–53. *See also* Electroretinography  
     microperimetry, 56  
     visual evoked potentials, 51, 55–56, 56f  
 Electroretinography (ERG), 44–53  
   about, 44, 44t  
   clinical considerations, 48–49f, 52–53  
   dark adaptometry comparison, 61  
   drug-induced abnormalities, 347  
   electrodes for, 44  
   full-field electroretinography, 45–48, 46f, 48–50f, 51, 52f  
   melanoma-associated retinopathy findings, 322–323  
   multifocal electroretinography, 49–51, 50f, 52f  
   ocular ischemic syndrome findings, 153  
   pattern electroretinography, 50f, 51, 52f  
 Ellipsoid, 11–13  
 Ellipsoidal mirror, 25–26, 25f  
 ELM. *See* External limiting membrane  
 ELOVL4 gene, 302  
 Elschnig spots, 134, 225, 225f  
 Embolism  
   arterial macroaneurysms and, 165–166  
   arterial occlusive disease etiology, 156, 157–158f, 159  
   choroidal perfusion abnormalities and, 222  
   differential diagnosis, 176, 192  
   talc, 347  
 Encephalofacial hemangiomas, 231  
 Enclosed ora bays, 374, 374f  
 Endogenous bacterial endophthalmitis, 270–271, 271f  
 Endogenous fungal endophthalmitis, 271, 273f  
 Endophthalmitis  
   antiangiogenic therapy complication, 91, 125  
   bacterial, 270–271, 271f  
   fungal, 271–272, 272–273f  
   intravitreal injection complication, 453  
   postoperative, 437–441, 438t, 439–440f  
   trauma-related, 407–409  
   yeast, 272, 273f  
 Endophthalmitis Vitrectomy Study (EVS), 438–439, 440f  
 En face scans, 26, 29  
 Enhanced depth imaging optical coherence tomography (EDI-OCT), 26, 39, 71, 74, 85, 86  
 Enhanced S-cone syndrome (ESCS), 53, 297, 298f  
 Enucleation, for penetrating ocular injury, 263  
 EOG. *See* Electro-oculography/electro-oculogram  
 EPA. *See* Eicosapentaenoic acid  
 Epiretinal membranes (ERMs), 351–354  
   about, 351  
   clinical findings, 351–353, 353f, 355f  
   differential diagnosis, 355  
   etiology and epidemiology, 351  
   management, 354, 431–432, 431–432f  
 Eplerenone, 221  
 Equatorial retina, 8  
 ERG. *See* Electroretinography  
 Ergot alkaloids, 342  
 ERMs. *See* Epiretinal membranes  
 Erythema chronicum migrans, 278  
 Erythroclastic (red blood cell–induced) glaucoma, 119  
 ESCD. *See* Enhanced S-cone syndrome

- Escherichia coli*, 270  
 ESCS. *See* Enhanced S-cone syndrome  
 ETDRS (study), 88, 100, 107*t*, 108–109, 115, 118, 122, 124, 127, 147  
 Ethambutol hydrochloride, 273  
 Ethylene glycol, 346  
 ETROP. *See* Early Treatment of Retinopathy of Prematurity  
 EVEREST studies, 85  
 Evisceration, for penetrating ocular injury, 263  
 EVS. *See* Endophthalmitis Vitrectomy Study  
 EXCITE (study), 66, 88  
 Exogenous fungal endophthalmitis, 271  
 Expulsive suprachoroidal hemorrhage, 443–444  
 External limiting membrane (ELM), 10*f*, 12*f*, 13, 14*f*  
 Extra-areal periphery, 8  
 Extraretinal fibrovascular proliferation, 114  
 Exudates  
   hard, 132, 145–146, 179, 185  
   macular, 133*f*, 134, 184, 184*f*  
   soft, 132  
 Exudative age-related macular degeneration (AMD), 67  
 Exudative retinal detachment  
   diagnostic features, 383*t*, 388–389, 389*f*  
   differential diagnosis, 389  
   drug-induced, 338, 341*f*  
   etiology, 389, 389*f*  
   familial exudative vitreoretinopathy association, 362  
   lupus vasculitis association, 262  
   photocoagulation-related, 424, 425  
   retinopathy of prematurity association, 210, 211*f*  
 Exudative retinopathy, 291, 294*f*  
 EyeArt (Eyenuk), 104  
 Eye Disease Case-Control Study, 135–136  
 Eye movement tracking, 28, 29, 56  
  
 FA. *See* Fluorescein angiography  
 Fabry disease, 328–329  
 Facioscapulohumeral muscular dystrophy, 179  
 FAF. *See* Fundus autofluorescence  
 Familial adenomatous polyposis (FAP), 320, 321*f*, 362–363, 362*t*, 363*f*  
 Familial cerebelloretinal angiomatosis, 181–182  
 Familial drusen, 304  
 Familial exudative vitreoretinopathy (FEVR), 179, 360, 362–363, 362*t*  
 Familial juvenile nephronophthisis, 320  
 FAP. *See* Familial adenomatous polyposis  
 Faricimab, 98  
 Farnsworth-Munsell 100-hue test, 58  
 Farnsworth Panel D-15 test, 58–59, 59*f*  
 Fat emboli/embolism, 156, 192  
 FAZ. *See* Foveal avascular zone  
 Fenofibrate, 111  
 FEVR. *See* Familial exudative vitreoretinopathy  
 ffERG. *See* Full-field electroretinography  
 Fibrovascular pigment epithelial detachment (PED), 77, 79, 81, 85, 91  
 FIELD (study), 100, 111  
 Fingolimod, 343–344  
 FIPTs. *See* Focal intraretinal periarteriolar transudates  
 FIREFLEYE (study), 208  
 “Fishnet” pigment deposition, 308*f*  
 Fish-shaped (pisciform) flecks, 300, 301*f*, 302  
 Flap tears, of retina, 376, 377*f*, 379*t*, 380  
 Flash visual evoked potentials (flash VEPs), 55, 56  
 Flaviviridae, 279  
 Flecken, 190, 191*f*  
 Floaters  
   in birdshot chorioretinopathy, 255  
   in cytomegalovirus retinitis, 267  
   management, 435  
   in posterior vitreous detachment, 350, 369–370  
   in retinal detachments, 382  
   in toxocariasis, 277  
   in toxoplasmic retinochoroiditis, 275  
 “Flower petal” pattern, 176, 177*f*  
 Fluconazole, for yeast endophthalmitis, 271  
 Flulike prodrome, 250, 254, 259  
 Fluocinolone acetonide implants, 126  
 Fluorescein angiography (FA), 32–38  
   about, 32–35, 33–34*f*  
   adverse effects of, 36–37  
   with fundus camera, 23  
   hyperfluorescence patterns, 34*f*, 35–36, 35*t*, 36–37*f*  
   hypofluorescence patterns, 34*f*, 35  
   landmarks, 8  
   laser therapy guidance with, 127  
   OCT angiography comparison, 29  
   scanning laser ophthalmoscopy and, 25  
 Fluorophores, 29–32  
 Fluoroquinolones, 408  
 “Flying saucer” sign, 326*f*, 334, 334*f*, 336*f*  
 Focal chorioretinitis, 271, 271*f*  
 Focal intraretinal periarteriolar transudates (FIPTs), 132, 132–133*f*  
 Focal laser photocoagulation, 122, 124, 127  
 Focal macular edema, 123  
 Footplates of Müller cells, 13  
 Form-deprivation errors, 245  
 Foscarnet, 267–268, 269, 270*t*  
 4:2:1 rule, for diabetic retinopathy, 108–109  
 Fovea  
   anatomy, 7–8, 7*f*, 8*t*, 10*f*, 210, 212*f*  
   atrophy of, 72–73  
   diabetic macular edema and, 121–122  
   imaging techniques, 35  
   photoreceptors of, 9  
 Fovea centralis, 7–8, 7*f*, 8*t*  
 Fovea plana, 212*f*  
 Foveal avascular zone (FAZ), 8, 83*f*, 171*f*, 181*f*  
 Foveal burns, 424  
 Foveal detachment, 355  
 Foveal schisis, 312  
 Foveola, 7–8, 7*f*, 8*t*, 9  
 Foveomacular retinitis, 412–413, 413*f*  
 “Frosted branch” angiitis, 267  
 Fuchs spot, 240  
 Fucosidosis, 329  
 Full-field (Ganzfeld) electroretinography (ffERG), 45–48, 46*f*, 48–50*f*, 51, 52*f*  
 Fundus  
   imaging techniques, 22–25, 24*f*, 27*f*, 29–32, 31*f*, 72, 72*f*, 74, 74*f*  
   rod-cone dystrophy findings, 291, 292*f*  
   “sunset glow” appearance of, 263

- Fundus albipunctatus, 286–287, 286–287*f*  
 Fundus autofluorescence (FAF), 23, 24*f*, 29–32, 31*f*, 72, 72*f*, 74, 74*f*  
 Fundus flavimaculatus, 47–48, 50*f*, 302, 306  
 Fundus pulverulentus, 306  
 Fungal endophthalmitis, 271–272, 272–273*f*, 408  
 Fungemia, 271  
*Fusarium* endophthalmitis, 272  
  
 GALILEO (study), 142*t*, 144  
 Ganciclovir, 267–269, 270*t*  
 Ganglion cell layer (GCL), 13, 14*f*, 343, 344*f*  
 Ganglion cell(s), 13  
 Ganglioside storage disease, 328  
 Ganzfeld ERG. *See* Full-field electroretinography  
 Gardner syndrome, 320. *See also* Familial adenomatous polyposis  
 Gastrointestinal tract disease, retinal degeneration associated with, 320, 321*f*  
 GATHER1 (study), 98  
 GATHER2 (study), 98  
 Gaucher disease, 328  
 GCA. *See* Giant cell arteritis  
 GCL. *See* Ganglion cell layer  
 GEFAL (study), 92*t*  
 Gene augmentation therapy, 456–457, 457*f*  
 General anesthesia, 53  
 Gene replacement therapy, 456–457, 457*f*  
 Gene therapy  
   about, 455–456  
   for age-related macular degeneration, 456*t*  
   for choroideremia, 299  
   current limitations, 458  
   for Leber congenital amaurosis, 297  
   for retinal dystrophies, 288, 290, 295, 456*t*  
   for Stargardt disease, 302  
   types, 456–458, 457*f*  
 Genetic heterogeneity, 288, 289  
 Genetics. *See also* X-linked disorders; *specific genes*  
   of age-related macular degeneration, 68–69, 304, 306  
   of cavernous hemangiomas, 186  
   of Coats disease, 178  
   of cone and cone–rod dystrophies, 297  
   of dystrophies, 288–289  
   of night vision abnormalities, 285–286  
   of von Hippel–Lindau syndrome, 181–182  
 Genetic testing, 68, 290  
 GENEVA (study), 141*t*, 145  
 Genome editing, 457, 457*f*, 458  
 Gentamicin, 342, 438  
 Geographic atrophy  
   choroidal, 226, 229  
   macular, 302, 302*f*, 306, 307, 307*f*  
   of retinal pigment epithelium, 66, 70, 71–73, 72*f*  
 Geographic choroiditis, 253  
 Ghost cell glaucoma, 119, 365  
 Ghost vessels, 226  
 Giant cell arteritis (GCA), 159–160, 222, 222–223*f*  
 Giant tears, of retina, 376  
 “Giraffe skin,” 232, 233*f*  
 Glaucoma  
   ghost cell, 365  
   management, 119, 440–441, 440*f*  
   myopia and, 246*f*, 247  
   neovascular, 188  
   nerve damage caused by, 392–393  
   open-angle, 136, 151  
   retinopathy of prematurity association, 210  
 Glia, 176, 177*f*  
 Glitazones, 343  
 Globe injuries, 395–415  
   abusive head trauma and, 411, 411*f*  
   classification, 395–396  
   closed, 397–401  
     choroidal rupture, 397, 398–399, 399–400*f*  
     classification, 395  
     commotio retinae, 397, 398, 398*f*  
     posttraumatic macular hole, 399–400  
     sequelae, 397–398  
     traumatic chorioretinal disruption, 401, 401*f*  
     vitreous hemorrhage, 400–401  
   evaluation, 396–397, 396*t*  
   foreign bodies, 404–407. *See also* Intraocular foreign bodies  
   management, 402–404  
   needle injuries, 445, 446*f*  
   open, 401–407  
     classification, 395–396  
     lacerating and penetrating, 395, 402, 408  
     perforating, 395, 402, 408  
     scleral rupture, 401–402  
     sequelae, 401  
   optic nerve head avulsion, 398, 410, 410*f*  
   photic damage, 412–415, 413*f*  
   posttraumatic endophthalmitis, 407–409  
   prognostication of, 409–410, 409*t*  
   sympathetic ophthalmia, 410  
 Glucosylceramide, 328  
 Glycemic control, 104–105, 106*t*, 123–124  
 GM<sub>2</sub> gangliosidosis type I, 328  
 Goldmann–Favre disease, 178  
 Goldmann–Favre syndrome, 297  
 Goldmann–Weekers (G–W) adaptometer, 61  
 Granulomas  
   choroidal, 273*f*  
   posterior pole, 277  
   in toxocariasis, 277  
 Granulomatosis with polyangiitis, 222, 223*f*  
 Green cones, 57  
 GRK1 gene, 287  
 Grönblad–Strandberg syndrome, 95  
 GUCY2D, and GUCA1A genes, 308  
 Guttering, 384*f*  
 G–W adaptometer. *See* Goldmann–Weekers adaptometer  
 Gyrate atrophy, 299–300, 300*f*  
  
*Haemophilus* spp, 441  
 Haller layer, 18  
 Handheld laser–pointer injury, 414–415, 414*f*  
 HARBOR (study), 66, 89*t*  
 Hard exudates, 132, 145–146, 179, 185  
 Hardy–Rand–Rittler plates, 58  
 HARRIER (study), 91  
 HAWK (study), 91  
 HbAs. *See* Sickle cell trait  
 HbSC. *See* Sickle cell–hemoglobin C disease

- HbSS disease. *See* Homozygous sickle cell disease  
 “Headlight in the fog,” 277*f*  
 Hearing loss, 319, 319*t*  
 Helicoid peripapillary choroidopathy, 253. *See also*  
   Serpiginous choroidopathy  
 HELLP (hemolysis, elevated liver enzymes, and low  
   platelet count) syndrome, 224*f*  
 Hemangioblastomas, 179, 182–185, 184–185*f*, 186  
 Hemangiomas, 186–187, 186–187*f*, 231, 232*f*  
 Hemeralopia, 295  
 Hemical central retinal vein occlusion (HRVO), 134, 138*f*  
 Hemoglobin, 419–420, 420*f*  
 Hemoglobin A<sub>1c</sub> (HgA<sub>1c</sub>), 105  
 Hemorrhage  
   diabetic retinopathy finding, 108, 114, 114*f*, 120  
   hypemias, 444  
   internal limiting membrane, 189, 189*f*  
   intraretinal. *See* Intraretinal hemorrhage  
   optic nerve, 190  
   preretinal, 114, 114*f*, 425  
   retinal, 342, 411, 411*f*  
   salmon-patch, 168, 170*f*  
   submacular, 93, 399, 434–435, 434–435*f*  
   subretinal, 85, 86, 190, 239, 398, 399*f*, 425  
   suprachoroidal, 397, 443–445, 444*f*  
   vitreous. *See* Vitreous hemorrhage  
 Hemorrhagic occlusive retinal vasculitis (HORV), 342  
 Henle fiber layer, 8*t*, 9, 176, 177*f*, 237  
 Heparan sulfate, 327  
 Hereditary dystrophies, 316*t*  
 Hereditary hyaloideoretinopathies with optically empty  
   vitreous, 360–361, 361*f*  
 Hermansky-Pudlak syndrome, 324  
 Herpes simplex virus (HSV), 268, 269, 270*t*  
 HEXA gene, 328  
 HgA<sub>1c</sub> (hemoglobin A<sub>1c</sub>), 105  
 High myopia. *See* Pathologic myopia  
 Histiocytic lymphoma. *See* Primary vitreoretinal  
   lymphoma  
*Histoplasma capsulatum*, 94  
 Histoplasmosis, 93–95, 94*f*  
 “Histo spots,” 94  
 HIV/AIDS  
   cytomegalovirus retinitis association, 267, 268  
   intraocular lymphoma risks, 264–265  
   non-CMV necrotizing herpetic retinitis association,  
     269  
   syphilitic retinochoroiditis association, 274  
   toxoplasmic retinochoroiditis association, 276  
 Hives, 37  
 HLA-A29, 255  
 HLA-B5, 261  
 HLA-B51, 261  
 Hollenhorst plaques, 157, 157*f*, 159  
 HOME (study), 77  
 Homocystinuria, 316*t*  
 Homozygous sickle cell (HbSS) disease, 168, 171, 174  
 HORIZON (study), 66, 89*t*  
 Horseshoe retinal tears, 376, 377, 377–378*f*, 379, 379*t*,  
   380*f*  
 HORV. *See* Hemorrhagic occlusive retinal vasculitis  
 HSV. *See* Herpes simplex virus  
 Human leukocyte antigens, 255, 261  
 Hunter syndrome, 317*t*, 327  
 Hurler-Scheie syndrome, 327  
 Hurler syndrome, 316*t*, 327  
 Hyalocytes, 7  
 Hyaloid artery, 358, 359*f*, 360  
 Hyaluronan (hyaluronic acid), 349  
 Hydroxychloroquine, 51, 52*f*, 333–335  
 Hyperacuity testing, 76–77  
 Hypercoagulability, 136  
 Hypercortisolism, 217  
 Hyperfluorescence, 30–32, 34*f*, 35–36, 35*t*, 36–37*f*, 110*f*  
 Hyperlipidemia, 105, 108, 124, 136  
 Hyperopia, 230, 231*t*, 232  
 Hypertension  
   asteroid hyalosis association, 364  
   central serous retinopathy association, 217  
   choroidal perfusion abnormalities and, 223–224, 225*f*  
   diabetic macular edema association, 124  
   diabetic retinopathy association, 105, 108  
   hypertensive choroidopathy, 133–134  
   hypertensive optic neuropathy, 133*f*, 134  
   hypertensive retinopathy, 132–133, 132–133*f*  
     malignant, 223  
   retinal vascular diseases association, 131–135  
 Hypertensive choroidopathy, 133–134  
 Hypertensive optic neuropathy, 133*f*, 134  
 Hypertensive retinopathy, 132–133, 132–133*f*  
 Hyperviscosity retinopathy, 150  
 Hypemias, 41, 174–175, 444  
 Hypofluorescence, 30, 31*f*, 34*f*, 35  
 Hypoglycemic drugs, 347  
 Hypogonadism, 318  
 Hypopyon, 440  
 Hypotension, fluorescein adverse effect, 37  
 Hypothyroidism, 136  
 Hypotony, 444  
 Hypotony maculopathy, 230, 231*t*  
 ICG. *See* Indocyanine green  
 ICGA. *See* Indocyanine green angiography  
 Ichthyosis, 320  
 ICROP. *See* International Classification of ROP  
 iCSNB. *See* Incomplete congenital stationary night  
   blindness  
 Idiopathic macular holes, 355–358, 356*f*, 432–433, 433*f*  
 Idiopathic multifocal choroiditis, 256  
 Idiopathic polypoidal choroidopathy, 34*f*, 426  
 Idiopathic retinal vasculitis, aneurysms, and  
   neuroretinitis (IRVAN), 176  
 IDx-DR (Digital Diagnostics), 104  
 IGA. *See* Indocyanine green angiography  
 ILM. *See* Internal limiting membrane  
 ILM inverted flap, 433  
 Imaging technologies, 23–41  
   about, 21  
   adaptive optics imaging, 32  
   fluorescein angiography, 32–38. *See also* Fluorescein  
     angiography  
   fundus autofluorescence, 23, 24*f*, 29–32, 31*f*, 72, 72*f*,  
     74, 74*f*  
   fundus camera imaging, 23, 24, 24*f*, 27*f*, 30–32  
   indocyanine green angiography, 23, 38–39, 38–39*f*  
   ophthalmoscopy, 22–23. *See also* Ophthalmoscopy

- optical coherence tomography, 26–28, 27–28*f*, 32.  
*See also* Optical coherence tomography
- optical coherence tomography angiography, 28–29, 30*f*
- scanning laser ophthalmoscopy, 24–26, 25*f*, 30–32, 31*f*
- ultrasonography, 26, 27*f*, 39–41, 40–41*f*, 397
- Immune checkpoint inhibitors, 338, 340*t*
- Implantable miniature telescopes, 93
- Implantable telescopes, 93
- Incomplete congenital stationary night blindness (iCSNB), 49*f*, 286, 286*f*
- Incontinentia pigmenti, 317*t*, 320
- Indirect ophthalmoscope/ophthalmoscopy, 22–23
- Indocyanine green (ICG), 38
- Indocyanine green angiography (ICGA), 23, 38–39, 38–39*f*
- Infantile neuronal ceroid lipofuscinoses (NCLs), 325–326
- Infantile nystagmus syndrome, 284
- Infantile Refsum disease, 327
- Infants. *See also specific congenital disorders*
- abusive head trauma in, 411, 411*f*
  - congenital toxoplasmosis in, 275
  - developmental abnormalities, 358–361
  - electrophysiologic testing modalities for, 47, 53, 56
  - electroretinography testing controls for, 47, 53
  - Leber congenital amaurosis in, 296
  - neuronal ceroid lipofuscinoses in, 325–326
  - Refsum disease in, 327
  - retinopathy of prematurity and, 193–194. *See also* Retinopathy of prematurity
  - trauma-related injuries, 377–379, 411, 411*f*
- Infectious diseases. *See also* Endophthalmitis
- Chikungunya virus retinitis, 281
  - cytomegalovirus retinitis, 267–268, 267*f*, 269, 270*t*
  - diffuse unilateral subacute neuroretinitis, 279, 280*f*
  - Ebola virus panuveitis, 281
  - non-CMV necrotizing herpetic retinitis, 268–269*f*, 268–270, 270*t*
  - ocular bartonellosis, 274, 276*f*
  - ocular Lyme borreliosis, 278–279
  - ocular tuberculosis, 272–273, 273*f*
  - syphilitic retinochoroiditis, 274, 275*f*
  - toxocariasis, 277–278, 278*f*, 360
  - toxoplasmic chorioretinitis, 274–277, 277*f*
  - trauma-related, 408
  - West Nile virus chorioretinitis, 279, 280*f*
  - Zika virus chorioretinitis, 279–281
- Inferior staphyloma syndrome, 245, 245*f*
- Inflammation, electroretinography findings, 47
- Inflammatory vasculitis, 261–262, 261*t*, 262*f*
- Inherited retinal diseases (IRDs), 455–458
- Inner nuclear layer (INL), 10*f*, 13, 14*f*, 45, 164
- Inner-outer segment junction, 13
- Inner plexiform layer (IPL), 10*f*, 13
- Inner retinal dystrophies, 310–313, 312*f*
- Inner segments, 11, 12*f*, 13
- Insulin-dependent diabetes mellitus, 100
- Interferogram, 26
- Interferon, 261, 342
- Intermediate capillary plexus, 14
- Intermediate uveitis, 277
- Internal limiting membrane (ILM)
- anatomy, 13, 14*f*
  - diabetic retinopathy findings, 108
  - myopia and, 237–239
  - sickle cell retinopathy findings, 168
  - Valsalva retinopathy hemorrhagic detachment, 189, 189*f*
- International Classification of ROP (ICROP), 194–198
- International Society for Clinical Electrophysiology of Vision (ISCEV), 44, 45–47, 46*f*
- International Vitreomacular Traction Study Classification System, 354*t*
- Intracranial hemangiomas, 185, 186
- Intraocular foreign bodies (IOFBs)
- about, 404–406, 404–406*f*, 407*t*
  - classification, 395
  - imaging techniques, 40, 41, 397
  - retained, 404*f*, 406–407, 407*t*, 408*f*, 441–442, 441*t*
- Intraocular lenses (IOLs), 41, 442–443
- Intraocular lymphoma, 264–267, 265–266*f*
- Intraocular pressure (IOP)
- decreased, 230, 382
  - elevated, 153, 174
  - intra vitreal injection complication, 453
  - risk factors, 145
  - in trauma patients, 396, 402, 404
- Intraretinal fluid, 77, 79*f*, 81*f*, 82, 96*f*
- Intraretinal hemorrhage
- Behçet disease finding, 261
  - branch retinal vein occlusion complication, 134, 135–136*f*
  - diabetic retinopathy finding, 108–109, 109*f*
  - radiation retinopathy complication, 188
- Intraretinal microvascular abnormalities (IRMAs), 108–109, 110*f*
- Intrascleral fixation, 442
- Intravitreal injections, 111, 117, 452–454, 452*f*, 453*t*, 457
- Inverted ILM technique, 238, 358
- IOFBs. *See* Intraocular foreign bodies
- IOLs. *See* Intraocular lenses
- Ionizing radiation, retinopathy caused by exposure to, 187–189
- IOP. *See* Intraocular pressure
- IPL. *See* Inner plexiform layer
- Ipsilateral facial nevus flammeus (port-wine birthmark), 231
- IRDs. *See* Inherited retinal diseases
- Iris burns, 424
- Iris fixation, 442
- Iris imaging techniques, 41
- Iris neovascularization
- diabetic retinopathy complication, 119
  - in ocular ischemic syndrome, 152–153
  - in radiation retinopathy, 188
  - in retinal artery occlusion, 162
  - in retinal vein occlusion, 148, 149, 152, 152*f*
- IRMAs. *See* Intraretinal microvascular abnormalities
- Iron, as foreign body, 406, 407, 407*t*, 408*f*
- IRVAN. *See* Idiopathic retinal vasculitis, aneurysms, and neuroretinitis
- Irvine-Gass syndrome, 176
- ISCEV. *See* International Society for Clinical Electrophysiology of Vision

- Ischemic (nonperfused) central retinal venous occlusion (CRVO), 148–149, 150f
- Ishihara plates, 58
- Isotretinoin, 347
- IVAN (study), 92t
- Jalili syndrome, 322
- Jeune syndrome, 320
- Joubert syndrome, 320
- Juxtafoveal retinal telangiectasia, 179, 180–181, 181–183f
- Kayser-Fleischer ring, 407
- KCNV2 gene, 53
- Kearns-Sayre syndrome, 317t, 330
- Keratitis, 272, 278
- Keratoconus, 296
- “Kissing choroidals” (appositional choroidal detachment), 40f, 443
- Klebsiella pneumoniae* endophthalmitis, 270
- Kyrleis plaques, 277f
- Lacerating injuries, 395, 402
- Lacquer cracks, 239, 240f
- Lamellar hole–associated epiretinal proliferation (LHEP), 27f, 352
- Lamina cribrosa dehiscence, 247, 247f
- L’Anthony Panel D-15 test, 58, 59
- Large colloid drusen, 304
- Laryngeal spasm, 37
- Laser ablation, 423. *See also* Photocoagulation
- Laser-pointer injury, 414–415, 414f
- Laser retinopexy, 422–423, 423f
- Late leakage from an undetermined source, 79
- Lattice degeneration
  - clinical findings, 371, 372f, 378f
  - etiology and epidemiology, 371
  - hereditary hyaloideoretinopathy finding, 361, 361f
  - management, 379, 379t, 380, 381
  - myopia finding, 236t, 237
  - retinal detachment association, 369, 371, 372–373f, 374, 378f
  - retinal pigment epithelium hyperplasia finding, 375
- LCA. *See* Leber congenital amaurosis
- L cones, 57
- LCPUFAs. *See* Long-chain polyunsaturated fatty acids
- Leakage hyperfluorescence, 34f, 35–36, 35t, 37f
- LEAVO (study), 143t, 144
- Leber congenital amaurosis (LCA), 296–297, 318, 458
- Leber hereditary optic neuropathy, 51
- Leber stellate neuroretinitis, 274
- Lensectomy, 360
- Lenses, 23, 421, 422t, 441–442, 441t
- Lentiviruses, 457
- “Leopard spotting,” 347
- Leptochoroid, 18
- Leukocoria, 178, 179f, 360
- Levofloxacin, 408
- LHEP. *See* Lamellar hole–associated epiretinal proliferation
- Lifestyle changes, for age-related macular degeneration, 76
- Ligament of Wieger, 5, 6f
- Light adaptation
  - in electro-oculography, 53–54, 54–55f
  - in electroretinography, 44t, 45, 46f, 47, 48–50f, 51, 52f
- Light injuries, 412–415, 413f
- Lightning injuries, 400
- Limiting membrane
  - external, 10f, 12f, 13, 14f
  - internal, 13, 14f, 168, 189–190, 237–239
  - middle, 13, 14f
- Lincoff rules, 382, 384f
- Lipofuscin, 29–30, 32, 300, 302, 304–305, 322f, 325
- Lipogranuloma, 179
- Liver disease, retinal degeneration associated with, 320
- Long-chain polyunsaturated fatty acids (LCPUFAs), 75
- Long-wavelength sensitive cones, 57
- Low-coherence light, 26
- LRP5* gene, 363f
- LUCAS (study), 92t
- LUCERNE (study), 98
- Lupus choroidopathy, 262
- Lupus vasculitis, 262, 262f
- Lutein, 75–76, 76t, 412
- Lyme borreliosis, 278–279
- Lymphomas, 264–267, 265–266f, 367
- Lysosomal metabolic diseases, 327–329, 328–329f
- Macroaneurysms, 132–133, 165–166, 166f, 176, 190
- Macrocysts, 382, 385f, 392
- MacTel Project, 180
- Macula
  - adaptive optics scanning laser ophthalmoscopy of, 11f
  - anatomy, 7–8, 7f, 8t
  - atrophy of, 292f, 295, 296f, 302, 302f, 306, 307, 307f
  - infarction of, 342
  - photoreceptors of, 10–11f, 11
- Macular branch retinal venous occlusion, 134, 136f
- Macular colobomas, 296
- Macular degeneration, 59, 66. *See also* Age-related macular degeneration
- Macular detachment, 303, 305f, 338–339, 392, 393f
- Macular dragging, 210, 210–212f
- Macular dystrophies, 300–310
  - adult-onset vitelliform lesions, 303, 304–305f
  - atypical and occult macular, 308–310, 310f
  - Best disease, 302–303, 302f
  - early-onset “drusenoid,” 303–306, 305–306f
  - electroretinography findings, 47–48, 48f, 56
  - pattern dystrophies, 306–308, 308–309f
  - Stargardt disease, 300–302, 301f. *See also* Stargardt disease
- Macular edema
  - cystoid, 176–178. *See also* Cystoid macular edema
  - diabetic, 121–128. *See also* Diabetic macular edema
  - drug-induced, 343–344, 347
  - in gyrate atrophy, 299
  - management, 123–128, 144, 144f, 178, 422, 443, 443f
  - photocoagulation complication, 118, 425
  - radiation retinopathy finding, 188
  - retinal venous occlusion association, 134, 136f, 139, 148
  - studies, 100
- Macular epiretinal membrane, 431–432, 431–432f
- Macular exudates, 133f, 134, 184, 184f
- Macular halo, 328, 329f

- Macular holes  
 full-thickness, 354*t*  
 idiopathic, 355–358, 356*f*, 432–433, 433*f*  
 imaging techniques, 27–28*f*  
 management, 358  
 myopia and, 238–239, 238*f*  
 posterior vitreous detachment sequelae, 350  
 retinal detachment association, 394, 394*f*  
 stages, 355–357, 356*f*  
 trauma-related, 397, 399–400
- Macular ischemia, 134
- Macular laser, 421–422. *See also* Photocoagulation
- Macular neovascularization (MNV), 66–67, 77–87, 78*f*, 82–84*f*
- Macular pits, 400
- Macular puckering, 353
- Macular schisis, 96*f*, 237–238, 238*f*, 391–392, 391*f*
- Macular telangiectasia, 86, 180–181, 181–183*f*, 346
- Macular translocation surgery, 93
- Maculopathy  
 acute exudative polymorphous vitelliform, 323  
 acute idiopathic, 250, 259–260, 260*f*  
 adult-onset vitelliform, 74, 74*f*, 177*f*  
 bull's-eye, 318, 326, 326*f*, 334, 336*f*  
 cellophane, 353  
 drug-induced, 334, 335, 340, 345–346  
 hypotony, 230, 231*t*  
 optic pit, 392–393, 392*f*  
 paracentral acute middle, 164, 165*f*, 259, 259*f*  
 retinal detachment association, 392–393, 393*f*  
 trauma-related, 411
- Magnetic resonance imaging (MRI), 397
- Malattia Leventinese drusen, 304–305
- Malignant hypertension, 223
- $\alpha$ -Mannosidosis, 316*t*
- MANTA (study), 92*t*
- MAPK pathway, inhibitors of, 338
- MAR. *See* Melanoma-associated retinopathy
- MARINA (study), 66, 88–89, 88*f*, 89*t*
- MARVEL (study), 143*t*
- Maternally inherited diabetes and deafness (MIDD), 317*t*, 330, 331*f*
- Maximal intensity projection, 29
- M cones, 57
- Mechanical photic damage, 412
- Medium-wavelength sensitive cones, 57
- MEK inhibitors. *See* Mitogen-activated protein kinase kinase inhibitors
- Melanin, 29–30, 32, 412, 419–420, 420*f*
- Melanolipofuscin, 32
- Melanolysosomes, 32
- Melanoma-associated retinopathy (MAR), 322–323
- Melanomas, 425
- Melanosomes, 15, 16*f*
- MELAS. *See* Mitochondrial encephalopathy, lactic acidosis, strokelike episodes
- Membranoproliferative glomerulonephritis type II, 306
- Meridional complex, 9, 9*f*
- Meridional folds, 9, 374, 374*f*, 377
- MESA (study), 66, 68
- Metabolic diseases, with retinal degeneration  
 albinism, 324–325, 325*f*  
 amino acid disorders, 329  
 central nervous system abnormalities, 316–317*t*, 325–329, 326–329*f*  
 mitochondrial disorders, 330, 330–331*f*
- Metamorphopsia, 74, 77, 95, 355
- Methanol toxicity, 343
- Methotrexate, 265
- Methoxyflurane, 346
- Methylphenidate, 346
- MEWDS. *See* Multiple evanescent white dot syndrome
- MFC. *See* Multifocal choroiditis
- MFCPU. *See* Multifocal choroiditis and panuveitis
- mfERG. *See* Multifocal electroretinography
- MFS8 gene, 310
- Microaneurysms, 108–109, 109*f*, 178, 179*f*, 188, 239
- Microcysts, 375–376
- Micronutrients, for age-related macular degeneration, 74, 75–76, 75–76*t*
- Microperimetry, 56
- Microphthalmos, 360
- Microvasculopathy, 342–343
- MIDD. *See* Maternally inherited diabetes and deafness
- Middle limiting membrane (MLM), 13, 14*f*
- Midget bipolar cell, 13
- “Milky Way” sign, 263, 264*f*
- Mineralocorticoid receptor antagonists, 221
- Miniature telescopes (implantable), 93
- Minimally classic choroidal neovascularization (CNV), 77, 79
- Mitochondrial disorders, 317*t*, 330, 330–331*f*
- Mitochondrial encephalopathy, lactic acidosis, strokelike episodes (MELAS), 317*t*, 330
- Mitogen-activated protein kinase (MEK)  
 inhibitors, 338, 340*t*, 341*f*
- Mitogen-activated protein kinase (MAPK) pathway,  
 inhibitors of, 338
- Mittendorf dot, 358
- Mizuo-Nakamura phenomenon, 287, 288*f*
- MLM. *See* Middle limiting membrane
- MNV. *See* Macular neovascularization
- Modified Scheie Classification of Hypertensive Retinopathy, 132
- Monochromatism, 284, 284*t*
- Morphopsia, 425
- Mosquito-borne diseases, 279–281
- “Mother spot,” 181. *See also* Phakomatoses
- Motion artifacts, 29
- Motion contrast, 28–29
- Moxifloxacin, 408
- MPSs. *See* Mucopolysaccharidoses
- MRI. *See* Magnetic resonance imaging
- Mucopolysaccharidoses (MPSs), 316*t*, 319*t*, 327
- Müller cells, 13, 14*f*, 180, 313, 390
- Multifocal choroiditis (MFC), 39, 95, 239, 250, 251*t*, 256–257, 256–257*f*, 272
- Multifocal choroiditis and panuveitis (MFCPU), 256
- Multifocal electroretinography (mfERG), 49–51, 50*f*, 52*f*
- Multifocal pattern dystrophy, 306
- Multiple evanescent white dot syndrome (MEWDS), 251*t*, 254–255, 254*f*
- Multiple sclerosis, 55
- Mycobacterium tuberculosis*, 272
- Myoid, 11, 13

- Myopia  
 age-related choroidal degeneration association, 227  
 drug-induced, 347  
 electroretinography testing and, 47  
 pathologic, 235–247. *See also* Pathologic myopia  
 retinopathy of prematurity association, 209–210
- Myopic macular schisis, 96*f*, 237–238, 238*f*
- Myotonic dystrophy, 316*t*
- Nanoparticles, 457
- NARP. *See* Neurogenic muscle weakness, ataxia, and retinitis pigmentosa
- National Stroke Association, 160
- Nausea and vomiting, fluorescein angiography as cause of, 36–37
- NCLs. *See* Neuronal ceroid lipofuscinoses
- Nd:YAG laser, 178, 412, 442, 443
- Near-infrared fundus autofluorescence, 32, 50*f*, 52*f*
- Near periphery, 8
- Necrotizing herpetic retinitis, 268–269*f*, 268–270, 270*t*
- Necrotizing retinochoroiditis, 275–276
- Needle injuries, 402, 445, 446*f*
- Neonatal adrenoleukodystrophy, 317*t*, 326, 327*f*
- Neoplasms, 230
- Neovascular age-related macular degeneration (AMD), 77–93  
 about, 77  
 anatomical classification, 77–78, 78*f*  
 clinical findings, 77  
 differential diagnosis, 82, 86  
 gene therapy for, 456*t*, 457  
 hemorrhage in, 434–435, 434*f*  
 imaging techniques, 78–85, 79–84*f*  
 management, 86–93, 88*f*, 89*t*, 92*t*  
 nonexudative, 78  
 polypoidal choroidal vasculopathy and, 85–86, 85–86*f*  
 risk factors, 70
- Neovascular glaucoma, 188
- Neovascularization  
 in branch retinal vein occlusion, 137, 145–146, 146–147*f*  
 in central retinal artery occlusion, 162  
 in central retinal vein occlusion, 137, 148, 149, 151–152  
 in central serous chorioretinopathy, 218  
 choroidal. *See* Choroidal neovascularization  
 iris. *See* Iris neovascularization  
 in ocular ischemic syndrome, 152–153, 152–153*f*, 154  
 optic nerve, 188  
 optic nerve head, 114, 137, 139*f*, 145–146, 146–147*f*, 188, 388*f*  
 pathogenesis, 135, 137  
 in peripheral retinal, 168, 169–171, 169*f*, 173*f*, 174*t*, 367  
 in retinopathy of prematurity, 196–197  
 sea fan lesions, 168, 171, 173*f*, 175  
 subretinal, 180
- Neovascularization elsewhere (NVE), 114, 114*f*
- Neovascularization of the disc (NVD), 114, 114*f*
- Nerve fiber layer (NFL)  
 anatomy, 10*f*, 13  
 cotton-wool spots of, 132, 132–133*f*, 154, 155*f*
- Nerve head sign of sickling, 171
- Neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP), 330
- Neuromuscular disorders, 316*t*, 319
- Neuronal ceroid lipofuscinoses (NCLs), 317*t*, 325–326, 326*f*
- Neuroretinitis, 134, 274
- NFL. *See* Nerve fiber layer
- Niacin, 343
- Nicotinic acid, 178, 343
- Niemann-Pick disease (NPD), 328, 329*f*
- Night blindness. *See* Nyctalopia
- N95, 51
- Nodular posterior scleritis, 230*f*
- Nonarteritic anterior ischemic optic neuropathy, visual evoked potentials in, 55
- Non-center-involved diabetic macular edema, 101, 122, 123*f*
- Non-CMV necrotizing herpetic retinitis, 268–269*f*, 268–270, 270*t*
- Noncontact indirect biomicroscopy, 22
- Noncystic retinal tufts, 371, 373*f*
- Nonexpulsive suprachoroidal hemorrhage, 444
- Nonexudative macular degeneration, 59, 66
- Nonexudative neovascular age-related macular degeneration (AMD), 78
- Non-Hodgkin diffuse large B-cell lymphoma, 264
- Non-insulin dependent diabetes mellitus, 100
- Nonischemic (perfused) central retinal venous occlusion (CRVO), 148, 149*f*
- Nonneovascular age-related macular degeneration (AMD), 69–77  
 about, 69  
 differential diagnosis, 73–74, 74*f*  
 drusen, 67, 67*f*, 69–71, 69*f*, 71*f*, 75  
 management, 74–77, 76*t*  
 prognosis, 75*t*  
 retinal pigment epithelium abnormalities, 71–73, 72–73*f*
- Nonperfused (ischemic) central retinal venous occlusion (CRVO), 148–149, 150*f*
- Nonproliferative diabetic retinopathy (NPDR), 108–111  
 defined, 100–101  
 examination schedules, 105*t*  
 progression of, 108–111, 109–110*f*  
 studies, 105  
 treatment, 111, 112–113*t*
- Nonproliferative sickle cell retinopathy (NPSR), 168, 169–172*f*
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 177*f*, 178
- Nonsyndromic panretinal dystrophies, 289–290
- North Carolina macular dystrophy, 308–309, 311*f*
- NPD. *See* Niemann-Pick disease
- NPDR. *See* Nonproliferative diabetic retinopathy
- NPSR. *See* Nonproliferative sickle cell retinopathy
- NR2E3 gene, 53, 297
- NRTIs. *See* Nucleoside reverse transcriptase inhibitors
- NSAIDs. *See* Nonsteroidal anti-inflammatory drugs
- Nuclear sclerotic cataract, 420–421, 451
- Nucleoside reverse transcriptase inhibitors (NRTIs), 337–338
- NVD. *See* Neovascularization of the disc
- NVE. *See* Neovascularization elsewhere

- Nyctalopia  
 about, 285–288, 286–288*f*  
 Bietti crystalline dystrophy association, 300  
 birdshot chorioretinopathy finding, 255  
 cone-rod dystrophy association, 296  
 drug-induced, 337, 347  
 electroretinography findings, 49*f*, 52  
 Goldmann-Favre disease and, 297  
 gyrate atrophy association, 299  
 melanoma-associated, 323  
 psychophysical evaluations, 61  
 rod-cone dystrophy association, 291  
 vitamin A deficiency and, 326
- Nystagmus, 56, 284–285, 296  
 NYX gene, 286
- OAKS (study), 97–98  
 OAT gene, 299  
 Occlusive ischemic syndrome, 108  
 Occlusive retinopathy, 342–343  
 Occlusive vascular diseases. *See* Arterial occlusive disease; Retinal venous occlusion
- Occult choroidal neovascularization (CNV), 37*f*, 77, 78*f*, 79  
 Occult macular dystrophies, 309–310  
 Occupational light toxicity, 414  
 OCT. *See* Optical coherence tomography  
 OCTA. *See* Optical coherence tomographic angiography
- Ocular albinism, 56, 284, 324  
 Ocular argyrosis, 347  
 Ocular bartonellosis, 274, 276*f*  
 Ocular globe trauma. *See* Globe injuries  
 Ocular histoplasmosis syndrome (OHS), 93–95, 94*f*  
 Ocular ischemic syndrome (OIS)  
 clinical findings, 152–153, 152–153*f*  
 course and prognosis, 154  
 differential diagnosis, 150, 153  
 etiology, 153  
 management, 154  
 Ocular Lyme borreliosis, 278–279  
 Ocular trauma. *See* Trauma  
 Ocular Trauma Score, 409, 409*t*  
 Ocular tuberculosis, 272–273, 273*f*  
 Oculocutaneous albinism, 56, 324  
 Oculodentodigital dysplasia (syndrome), 316*t*  
 Oculodigital reflex, 296  
 Oguchi disease, 287  
 “Ohno” sign, 263  
 OHS. *See* Ocular histoplasmosis syndrome  
 OIS. *See* Ocular ischemic syndrome  
 Olivopontocerebellar atrophy, 316*t*  
 Omega-3 and omega-6 fatty acids, 75, 294  
 OMIC. *See* Ophthalmic Mutual Insurance Company  
 OMIM. *See* Online Mendelian Inheritance in Man website
- Onion sign, 81  
 ONL. *See* Outer nuclear layer  
 Online Mendelian Inheritance in Man (OMIM) website, 288  
 Onset-offset (pattern-reversal pattern) visual evoked potentials (VEPs), 55, 56, 56*f*  
 Opacities, vitreous, 364–367, 364*f*, 366*f*, 429, 435  
 Open-angle glaucoma, 136, 151
- Open-globe injuries, 401–407  
 classification, 395–396  
 evaluations, 396–397, 396*t*  
 lacerating and penetrating, 263, 395, 402, 408  
 management, 402–404  
 perforating, 395, 402, 408  
 prognostication, 409–410, 409*t*  
 scleral rupture, 401–402  
 sequelae, 401
- Operculated retinal holes, 376, 377, 379*t*, 380  
 Operculum, 356–357*f*, 357, 378*f*  
 Ophthalmic artery occlusion, 162–163, 164*f*  
 Ophthalmic Mutual Insurance Company (OMIC), 213  
 Ophthalmoscopy  
 direct, 22  
 indirect, 22–23  
 scanning laser, 24–26, 25*f*, 30–32, 31*f*
- OPL. *See* Outer plexiform layer  
 Opportunistic infections, 267  
 Optical coherence tomography (OCT)  
 about, 26–28, 27–28*f*, 32  
 angiography, 28–29, 30*f*  
 laser therapy guidance with, 127  
 spectral-domain, 26–27, 50*f*, 52*f*
- Optical coherence tomography angiography (OCTA), 28–29, 30*f*
- Optic atrophy, 51, 188  
 Optic disc drusen, 40, 95, 95*f*  
 Optic nerve  
 anatomy, 13  
 electrophysiologic evaluations, 55  
 myopia and, 246–247, 246–247*f*  
 racemose hemangiomas of, 186, 186*f*
- Optic nerve head (optic disc)  
 avulsion of, 398, 410, 410*f*  
 drusen of, 291, 304  
 edema, 120, 133*f*, 134, 188, 190  
 hemangiomas of, 186  
 hemorrhage and, 190, 398, 399*f*  
 neovascularization of, 114, 137, 139*f*, 145–146, 146–147*f*, 188, 388*f*
- Optic nerve pit(s), 392–393, 393*f*  
 Optic neuritis, 55, 56*f*  
 Optic neuropathy, 133*f*, 134, 188, 343, 424  
 Optic pit maculopathy, 392–393, 393*f*  
 Optociliary shunt vessels, 137–138, 139*f*  
 Optogenetics, 457*f*, 458  
 Ora bays, 9, 9*f*, 374, 374*f*, 377  
 Oral contraceptives, 342  
 Orange reflex, 158  
 Ora serrata, 8, 9*f*, 22  
 Ornithine, 299  
 Oscillatory potentials, 47, 49*f*, 51  
 Outer nuclear layer (ONL), 10*f*  
 Outer plexiform layer, 10*f*, 13, 14  
 Outer retinal tubulation, 73, 73*f*  
 Outer-schisis-layer holes, 391*f*  
 Outer segments, 12*f*, 13, 15–17, 16*f*  
 Oxalate, 346  
 Oxygen, 7, 13, 18, 199
- Pachychoroid, 18, 85  
 Pachychoroid phenotype, 219

- Pachychoroid pigment epitheliopathy, 219  
Pachychoroid spectrum, 219–220  
Pachyvessel, 219  
Paclitaxel, 343  
Paget disease of bone, 95  
PAMM. *See* Paracentral acute middle maculopathy  
Pancreatitis, 192  
Panel tests, 58–59, 59f  
Panophthalmitis, 271  
PANORAMA (study), 100, 111  
Panretinal dystrophies, 289–290, 291  
Panretinal photocoagulation (PRP)  
  about, 422–423, 423f  
  diabetic macular edema treatment, 127  
  diabetic retinopathy treatment, 111, 112t, 115, 116–120, 119f  
  ocular ischemic syndrome treatment, 154  
  retinal venous occlusion treatment, 140t, 146, 151  
Panuveitis  
  Behçet disease association, 261  
  differential diagnosis, 95  
  Ebola virus association, 281  
  imaging techniques, 39  
  syphilitic, 274  
  toxocariasis association, 277  
  Vogt-Koyanagi-Harada disease association, 263  
Papilledema, 231t  
Papillopathy, 120  
Paracentral acute middle maculopathy (PAMM), 164, 165f, 259, 259f  
Paracentral scotomata (scotomas), 77, 95, 127, 259, 412, 413–414  
Parafovea, 7f, 8, 8t, 168  
Paraneoplastic retinopathies, 322–323, 323f  
Parasitic infections, 279  
Parinaud oculoglandular syndrome, 274  
Pars plana, 9, 9f  
Pars plana vitrectomy  
  complications, 451–452, 451t  
  diabetic macular edema treatment, 127  
  diabetic retinopathy treatment, 119  
  foreign-body removal, 406  
  macular hole treatment, 358  
  principles of, 429–431, 430t  
  retinal venous occlusion treatment, 148, 152  
  vitreous hemorrhage association, 365  
Patch atrophy, 243  
Patellar fossa, 5  
Patent foramen ovale, 15f  
Pathologic myopia, 235–247  
  about, 235  
  clinical findings, 235, 236t  
  management, 238–240, 241f  
  pathogenesis  
    Bruch membrane, 239, 240f, 246, 246f  
    choroid, 239–243, 240–244f  
    optic nerve, 246–247, 246–247f  
    retina, 236–239, 237–238f  
    sclera, 237f, 243–246, 245f  
Pattern-appearance stimulation, of visual evoked potentials, 56  
Pattern dystrophies, 74, 303, 304f, 306–308, 308–309f  
Pattern electroretinography (PERG), 50f, 51, 52f  
Pattern-reversal pattern (onset-offset) visual evoked potentials (VEPs), 55, 56, 56f  
Pattern scanners, 423  
Patton lines, 230, 231t  
Paving-stone degeneration, 374–375, 375f  
PCARE mutation, 292f  
PCIOs. *See* Posterior chamber intraocular lenses  
PCV. *See* Polypoidal choroidal vasculopathy  
PDE-5. *See* Phosphodiesterase-5 inhibitors  
PDR. *See* Proliferative diabetic retinopathy  
PDT. *See* Photodynamic therapy  
Peau d'orange, 95, 95f  
PED. *See* Pigment epithelial detachment  
Pediatric eye trauma, 377–379  
Pegaptanib, 88  
Pegcetacoplan, 97  
Pelizaeus-Merzbacher disease, 317t  
Pelli-Robson test, 60, 60f  
Penetrating injuries, 263, 395, 402, 408  
Penicillin, 279  
Pentosan polysulfate, 340, 340t, 342f  
Perfluorocarbon, 430, 449, 451  
Perfluoropropane, 430  
Perforating injuries, 395, 402, 408  
Perfused central retinal venous occlusion (CRVO), 148, 149f  
PERG. *See* Pattern electroretinography  
Pericytes, 102  
Perifovea, 7f, 8, 8t, 176  
Peripapillary intrachoroidal cavitations, 243, 244f  
Peripheral anterior synechiae, 119  
Peripheral cystoid degeneration, 375–376, 390–391  
Peripheral granuloma, in toxocariasis, 277  
Peripheral necrotizing herpetic retinitis, 268f  
Peripheral retina, 8  
Peripheral retinal excavations, 374  
Peripheral retinal neovascularization  
  amyloidosis finding, 367  
  differential diagnosis, 174t  
  in sickle cell retinopathy, 168, 169–171, 169f, 173f  
Peripheral retinal photocoagulation, 422–423, 423f.  
  *See also* Photocoagulation  
Peripheral schisis, 310  
Peripheral vision field loss, 118, 291  
Periphlebitis, 267  
Peroxisomal disorders, 326–327  
Persistent fetal vasculature (PFV), 360  
Persistent placoid maculopathy, 252  
Petaloid pattern, 176, 177f  
P50, 51  
PFV. *See* Persistent fetal vasculature  
Phacoemulsification, 441  
Phagocytosis, 13, 16–17, 32, 217, 218f  
Phakomatoses, 181–187  
  about, 181  
  retinal cavernous hemangioma, 186–187, 187f  
  von Hippel-Lindau syndrome, 181–185, 184–185f  
  Wyburn-Mason syndrome, 186, 186f  
Phenothiazines, 337, 338f  
Phlebectasias, 178  
Phosphodiesterase-5 inhibitors (PDE-5), 347  
Photoc damage, 412–415, 413f  
Photochemical injuries, 412

- Photocoagulation  
 aneurysm treatment, 165–166  
 Coats disease treatment, 179  
 complications, 175, 424–425  
 cystoid macular edema treatment, 178  
 diabetic macular edema treatment, 112*t*, 122, 124, 125*f*, 126, 127–128  
 diabetic retinopathy treatment, 104, 107*t*, 111, 112*t*, 115, 116–120, 118–119*f*, 118*f*  
 hemangioma treatment, 231  
 myopic choroidal neovascularization treatment, 239  
 neovascular age-related macular degeneration treatment, 87  
 principles of, 419–425  
   alternative laser delivery systems, 423–424  
   anesthesia for, 421  
   laser wavelength, 420–421  
   lenses, 421, 422*f*  
   overview, 419, 420*f*  
   parameters and indications, 421–423  
 radiation retinopathy treatment, 189  
 retinal break treatment, 379  
 retinal cavernous hemangioma treatment, 187  
 retinal venous occlusion treatment, 139, 140*t*, 145, 146, 147, 147*f*, 151  
 retinopathy of prematurity treatment, 200*f*, 205*t*, 207, 208  
 sickle cell retinopathy treatment, 175  
 types of, 421–423  
 von Hippel–Lindau syndrome treatment, 184
- Photodynamic therapy (PDT)  
 about, 426  
 age-related macular degeneration treatment, 87, 93  
 central serous chorioretinopathy treatment, 221  
 choroidal neovascularization treatment, 239, 241*f*  
 combination treatments that include, 93  
 complications, 426  
 diabetic retinopathy treatment, 88  
 hemangioma treatment, 231  
 pathologic myopia treatment, 96  
 polypoidal choroidal vasculopathy treatment, 85, 426  
 von Hippel–Lindau syndrome treatment, 184–185, 185*f*
- Photophobia, 52–53, 295
- Photopsias. *See also* Floaters  
 electrophysiologic evaluations, 53  
 photocoagulation adverse effect, 118  
 in posterior vitreous detachment, 369–370  
 in retinal detachments, 382
- Photoreceptor dystrophies  
 cone dystrophies, 47–48, 48*f*, 52–53  
 cone–rod dystrophies, 47–48, 295–296, 296*f*, 322  
 rod–cone, 291–295, 292–295*f*. *See also* Retinitis pigmentosa
- Photoreceptor(s). *See also* Cone(s); Rod(s)  
 age-related changes, 67, 67*f*  
 anatomy, 11–13, 12*f*, 15–17, 16*f*  
 density and distribution of, 9–11, 10–11*f*  
 electroretinography testing of, 45–51, 46*f*, 48–49*f*  
 gene therapy for, 458  
 imaging, 32  
 phagocytosis of, 32  
 posttraumatic injuries, 398  
 shaggy, 218*f*
- Photo-ROP Cooperative Group, 203
- Phototoxicity from ophthalmic instrumentation, 413–414
- PHP. *See* Preferential hyperacuity perimetry
- Physiological testing. *See* Electrophysiologic testing
- PIC. *See* Punctate inner choroiditis
- PIER (study), 66, 88, 88*f*
- Pigmentary maculopathy, 340, 411
- Pigmentary retinopathy  
 about, 290, 315  
 didanosine complication, 340*t*  
 phenothiazine complication, 337  
 syndromic  
   Bardet-Biedl syndrome association, 318–319, 318*f*  
   dental disease association, 322  
   dermatologic disease association, 320–322, 322*f*  
   gastrointestinal tract disease association, 320, 321*f*  
   liver disease association, 320  
   metabolic diseases with CNS abnormalities, 325, 326, 327  
   mitochondrial disorder association, 330  
   neuromuscular disorder association, 316*t*, 319, 319*t*  
   overview, 315, 316–317*t*  
   Usher syndrome association, 319, 319*t*  
   unilateral, 292–293
- Pigmented paravenous retinopathy, 293
- Pigment epithelial detachment (PED)  
 drusen formation and, 70  
 fibrovascular, 77, 79, 81, 85, 91  
 imaging, 80–81*f*, 81  
 serous, 81  
 subfoveal, 81*f*  
 vascularized serous, 79, 80*f*
- Pigment granules, 365
- Pioglitazone, 343
- PIOL. *See* Primary intraocular lymphoma
- Pisciform (fish-shaped) flecks, 300, 301*f*, 302
- PLANET (study), 66, 85
- Platelet-fibrin emboli, 156, 158*f*
- “Plucked chicken” skin, 96, 321
- Plus disease, 195*t*, 197*f*, 198*f*
- Pneumatic displacement, 93
- Pneumatic retinopexy, 447–448, 447*f*
- POHS. *See* Presumed ocular histoplasmosis syndrome
- Poliosis, 263
- Polydactyly, 318, 318*f*
- Polypoidal choroidal vasculopathy (PCV)  
 description of, 85–86, 85–86*f*  
 differential diagnosis, 218, 219  
 imaging techniques, 39, 39*f*  
 management, 85, 93
- Polypoidal choroidopathy, 34*f*
- Pooling hyperfluorescence, 34*f*, 35, 35*t*, 36
- “Poppers” (alkyl nitrites), 340, 340*t*, 341*f*
- PORN. *See* Progressive outer retinal necrosis syndrome
- Port-wine birthmark (ipsilateral facial nevus flammeus), 231
- Posterior (aggressive) retinopathy of prematurity, 195*t*, 196–197, 199*f*
- Posterior chamber intraocular lenses (PCIOLs), 442–443

- Posterior ciliary arteries, 17–18, 18*f*, 222, 223*f*  
 Posterior perifoveal vitreous detachment, 350  
 Posterior persistent fetal vasculature, 360  
 Posterior pole, 7*f*, 8*t*  
 Posterior pole granuloma, 277  
 Posterior scleritis, 230*f*  
 Posterior segment, blunt trauma sequelae, 397–398, 401.  
   *See also* Closed-globe injuries; Open-globe injuries  
 Posterior uveal bleeding syndrome, 85. *See also*  
   Polypoidal choroidal vasculopathy  
 Posterior uveitis, 34*f*, 47, 265  
 Posterior vitreoschisis, 350, 351  
 Posterior vitreous detachment (PVD)  
   about, 349  
   asteroid hyalosis association, 364  
   cholesterolosis association, 366  
   clinical findings, 369–370, 370*f*  
   diagnosis, 350, 350–352*f*  
   differential diagnosis, 190  
   epiretinal membranes and, 351–354, 353*f*, 355,  
     355*f*  
   etiology and epidemiology, 349–350  
   idiopathic macular holes, 355–358, 356–357*f*  
   management, 370–371  
   myopia macular retinoschisis in, 237–238, 238*f*  
   retinal tears caused by, 369  
   vitreomacular traction diseases and, 350, 351*f*,  
     354–355, 354*t*, 355*f*  
   vitreous hemorrhage association, 365  
 Postoperative endophthalmitis, 437–441, 438*t*,  
   439–440*f*  
 Posttraumatic endophthalmitis, 407–409  
 Posttraumatic macular hole, 399–400  
 Precortical vitreous pocket, 6*f*, 7  
 Prednisone, 276  
 Preeclampsia, 223–225, 224*f*  
 Preferential hyperacuity perimetry (PHP), 77  
 Pregnancy  
   central serous retinopathy association, 217  
   diabetic retinopathy association, 103–104, 104*t*  
   diagnostic imaging precautions, 38  
   premature births, 193–194, 199  
   *Toxoplasma gondii* exposure, 275  
   Zika virus exposure during, 279–281  
 Premacular bursa, 6*f*, 7  
 Premature births, 193–194, 199  
 Prepapillary vascular loops, 358, 359*f*  
 Preretinal hemorrhage, 114, 114*f*, 425  
 Preretinal macular fibrosis, 353  
 Preretinal tract, 5  
 Preserved para-arteriolar retinal pigment epithelium  
   phenotype, 179  
 Presumed ocular histoplasmosis syndrome (POHS),  
   94  
 Prethreshold disease, 194, 199*t*  
 Primary intraocular lymphoma (PIOL), 264  
 Primary repair, of open-globe injuries, 403  
 Primary vitrectomy, 449–450, 449*f*  
 Primary vitreoretinal lymphoma, 264–265  
 Procinamide, 342  
 Progressive outer retinal necrosis (PORN) syndrome,  
   268, 269*f*  
 Projection artifacts, 29  
 Proliferative diabetic retinopathy (PDR), 111–120  
   complications, 119–120  
   epidemiology, 101  
   eye examination schedules, 105*t*  
   high-risk characteristics, 114–115, 114*f*  
   management  
     complications, 175  
     goals of, 115  
     mandatory treatment, 114–115, 114*f*  
     nonpharmacologic, 104, 117–119, 118–119*f*  
     pharmacologic, 115–117, 116*f*  
     neovascularization and, 169–171  
     pregnancy-related, 104  
     progression of, 111, 114–115  
     studies, 105  
     traction retinal detachment association, 388*f*  
     vitreous hemorrhage association, 365  
 Proliferative vitreoretinopathy (PVR), 382, 386*f*, 387*t*, 401  
*PROM1* gene, 302, 309  
*Propionibacterium acnes*, 438, 440*f*  
 Prostaglandin F<sub>2α</sub> analogs, 344  
 Prosthesis, retinal, 295  
 Protan red-green color deficiency, 57, 59  
 PRP. *See* Panretinal photocoagulation  
*PRPH2* gene, 302, 303, 308  
 Pseudodrusen  
   age-related choroidal degeneration association, 229,  
     229*f*  
   imaging techniques, 25  
   in pseudoxanthoma elasticum, 226  
   reticular, 70, 71*f*  
 “Pseudohole” appearance, 351–352, 431–432*f*  
 Pseudoisochromatic plates, 58, 58*f*  
 Pseudophakia, 381, 446  
 Pseudophakic cystoid macular edema, 176–178, 177*f*  
 Pseudo-POHS. *See* Pseudo-presumed ocular  
   histoplasmosis syndrome  
 Pseudo-presumed ocular histoplasmosis syndrome  
   (pseudo-POHS), 256  
 Pseudoxanthoma elasticum (PXE), 95–96, 95*f*, 226,  
   227*f*, 308, 321  
 Psychophysical tests, 56–61  
   about, 56–57  
   color vision, 57–59, 58–59*f*  
   contrast sensitivity, 59–60, 60*f*  
   dark adaptometry, 61  
 PULSAR (study), 98  
 “Punched-out” chorioretinal scars, 94  
 Punctate inner choroiditis (PIC), 250, 251*t*, 256  
 Pupillary dilation, 118  
 Purtscher flecken, 190, 191*f*  
 Purtscher-like retinopathy, 190*t*, 191–192, 191*f*  
 Purtscher retinopathy, 190, 190*t*  
 PVD. *See* Posterior vitreous detachment  
 PVR. *See* Proliferative vitreoretinopathy  
 PXE. *See* Pseudoxanthoma elasticum  
 Pyrimethamine, 276  
 Quadruple therapy, for toxoplasmic retinochoroiditis, 276  
 Quinine, 343, 344*f*  
*R9AP* gene, 53  
 Rab escort protein (REP1), 299

- Rab proteins, 299
- Race and ethnicity  
 age-related macular degeneration prevalence, 68  
 Behçet disease and, 261  
 birdshot chorioretinopathy and, 255  
 diabetic retinopathy and, 101–102  
 drug-induced toxicity and, 334  
 polypoidal choroidal vasculopathy and, 85  
 sickle cell hemoglobinopathies and, 167, 174–175  
 systemic lupus erythematosus and, 262  
 Vogt-Koyanagi-Harada disease and, 263
- Racemose hemangiomas, 186, 186f
- Radial peripapillary capillary network, 13
- Radial striae, 310, 312
- Radiation, 187–189, 231, 265
- Radiation papillopathy, 134
- Radiation retinopathy, 179, 187–189, 188f
- RAINBOW (study), 206t, 208, 209
- Ranibizumab  
 age-related macular degeneration treatment, 66, 85, 88–93, 88f, 89t, 92t  
 diabetic macular edema treatment, 112t, 124–125, 125f  
 diabetic retinopathy treatment, 88, 111, 115  
 retinal venous occlusion treatment, 141–143t, 144, 145  
 retinopathy of prematurity treatment, 206t, 208  
 route of administration, 452
- RAPs. *See* Retinal angiomatous proliferations
- RDH5* gene, 286
- Reactive retinal astrocytic tumor, 179
- Recurrent multifocal choroiditis (RMC), 256
- Red blood cell–induced (erythroclastic) glaucoma, 119
- Red cones, 57
- Red-green color deficiency, 57
- Refractile spots, 168
- Refsum disease, 316t, 319t, 324, 327
- Relentless placoid chorioretinitis, 252
- Renal diseases, 318, 320, 334
- Renal-retinal dysplasia, 320
- REP1. *See* Rab escort protein
- Retained foreign bodies, 404f, 406–407, 407t, 408f, 441–442, 441t
- Reticular degenerative retinoschisis, 390, 390f, 391
- Reticular peripheral cystoid degeneration, 375–376, 389–390
- Reticular pseudodrusen, 70, 71f
- Reticular-type pattern dystrophy, 306, 308f
- Reticulum cell sarcoma. *See* Primary vitreoretinal lymphoma
- Retina  
 anatomy. *See also* Retinal pigment epithelium layers and neurosensory elements, 9–13, 10–12f, 14f, 15–17, 16f  
 topography, 7–8, 7f, 7t, 9f  
 vasculature and oxygen supply, 13–14, 15f, 18–19, 193, 194  
 electrophysiologic testing, 43–56. *See also* Electrophysiologic testing  
 myopia and, 236–249, 237–238f  
 psychophysical testing of. *See* Psychophysical tests
- Retinal angiomatous proliferations (RAPs), 39, 78, 79
- Retinal artery occlusion. *See* Arterial occlusive disease
- Retinal breaks  
 classification, 376, 377f  
 clinical findings, 384f  
 defined, 369  
 etiology, 376–379, 377–378f  
 formation of, 369, 371, 378f  
 management  
 closure, 385–387  
 prophylactic treatment, 379–381, 379t, 380f
- Retinal burns, 412, 424
- Retinal capillaries, 109, 122, 176
- Retinal cavernous hemangioma, 186–187, 187f
- Retinal degeneration  
 about, 315  
 metabolic diseases with  
 albinism, 324–325  
 amino acid disorders, 329  
 central nervous system abnormalities, 316–317t, 325–329, 326–329f  
 mitochondrial disorders, 330, 330–331f  
 with systemic involvement, 315–324. *See also* Systemic diseases, with retinal degeneration
- Retinal detachment, 369–394. *See also* Exudative retinal detachment  
 about, 369  
 bullous, 310  
 causes, 115, 120  
 central serous chorioretinopathy as cause of, 215  
 classification, 381–382  
 complex, 450  
 differential diagnosis, 382, 389–391, 390–391f  
 electroretinography findings, 47  
 fellow-eye risk, 381  
 hypertension and, 223  
 hypertensive choroidopathy association, 134  
 imaging techniques, 34f, 40  
 lesions, not predisposing to, 374–376, 375f  
 lesions, predisposing to, 371–374, 372–374f  
 macular lesion association, 392–394, 393–394f  
 management  
 outcomes following surgery, 450–451  
 surgery, 436–437, 436f, 445–451, 446–449f  
 myopia and, 237  
 non-CMV necrotizing herpetic retinitis association, 269–270  
 posterior vitreous detachment and, 369–371, 370f  
 prevention, 379–381, 379t  
 psychophysical tests, 56–61. *See also* Psychophysical tests  
 retained lens fragment complication, 442  
 retinal breaks and  
 prophylactic treatment, 379–381, 379t, 380f  
 types of, 376–379, 377–378f  
 retinal tears and, 365  
 retinopathy of prematurity association, 210, 210–211f  
 sickle cell retinopathy association, 175  
 Stickler syndrome association, 361  
 trauma-related, 397, 401  
 types of. *See* Exudative retinal detachment;  
 Rhegmatogenous retinal detachment; Traction retinal detachment  
 von Hippel–Lindau syndrome association, 184, 184f

- Retinal dialyses, 376, 377, 379*t*, 382, 385*f*
- Retinal dystrophies  
 classification, 289  
 diagnostic considerations, 289–290  
 genetics, 290  
 management, 290–291  
 photoreceptor dystrophies  
   cone and cone-rod, 295–296, 296*f*  
   rod-cone, 287, 291–295, 292–295*f*  
 systemic disease association, 318  
 terminology, 288  
 X-linked retinoschisis, 310–313, 312*f*
- Retinal folds  
 developmental abnormality, 360, 362  
 proliferative vitreoretinopathy finding, 387*t*, 389  
 trauma-related, 411
- Retinal grafts, 358
- Retinal hemangioblastomas (RH), 179, 181–185, 184–185*f*, 186
- Retinal hemorrhage, 342, 411, 411*f*
- Retinal holes  
 atrophic, 371, 372–373*f*, 376, 378*f*, 379*t*, 380  
 photocoagulation-related, 424–425
- Retinal Information Network, 288
- Retinal ischemia, 108, 111, 145, 160–161, 161*f*
- Retinal pigment epithelium (RPE)  
 age-related changes, 67, 67*f*, 69–70, 69*f*, 71–73, 72–73*f*, 77  
 anatomy and physiology of, 15–17, 16*f*, 18  
 atrophy of, 66, 70, 71–73, 72*f*, 119*f*, 226, 303, 331*f*, 425  
 Bardet-Biedl syndrome, 318–319, 318*f*  
 central serous chorioretinopathy and, 215, 216–217, 216*f*, 218*f*  
 choroidal perfusion abnormalities association, 226  
 choroidal thinning and, 242–243, 243*f*  
 degeneration of, 289–290  
 depigmentation of, 257, 258*f*  
 detachment of. *See* Pigment epithelial detachment  
 drug-induced abnormalities, 333–337, 334–336*f*, 338*f*  
 electrophysiologic evaluations, 53–55, 54*f*  
 functions, 13, 15–17, 32, 217, 218*f*  
 hyperpigmentation of, 119*f*  
 hyperplasia of, 372, 375  
 hypertrophy of, 375  
 overview, 315, 316–317*t*  
 pigmentary retinopathy and, 315–322, 316–317*t*.  
   *See also* Pigmentary retinopathy  
 Stargardt disease findings, 300, 301*f*, 302  
 tears, 30, 31–32, 31*f*, 91
- Retinal precipitates, 274
- Retinal tears. *See also* Retinal breaks  
 anatomy, 8  
 defined, 369  
 formation of, 378*f*  
 imaging techniques, 40  
 lesions, predisposing, 371, 372, 374  
 management, 379–380, 379*t*, 423, 427  
 myopia and, 237  
 retained lens fragment complication, 442  
 retinopathy of prematurity association, 212*f*  
 Stickler syndrome association, 361  
 trauma-related, 397  
 vitreous hemorrhage association, 365
- Retinal telangiectasia, 178, 179*f*, 186
- Retinal tufts, 371–372, 373*f*
- Retinal vasculitis, 29, 34*f*, 175–176, 175*f*
- Retinal vasoproliferative tumor (VPT), 179, 185
- Retinal venous occlusion (RVO), 134–152  
 about, 134  
 branch, 145–148. *See also* Branch retinal vein occlusion  
   occlusion  
 central. *See* Central retinal vein occlusion  
 clinical findings, 134, 135–138*f*  
 complications, 137–138, 139*f*  
 cystoid macular edema etiology, 176  
 differential diagnosis, 179  
 drug-induced, 342  
 management, 138–139, 140–143*t*, 144–145, 144*f*  
 pathogenesis, 134–135  
 risk factors, 135–137
- Retinitis, 249–281  
 about, 249  
 Chikungunya virus, 281  
 chorioretinitis sclopetaria, 398, 401, 401*f*  
 cytomegalovirus, 267–268, 267*f*, 269, 270*t*  
 infectious diseases, 267–280  
 necrotizing herpetic, 268–269*f*, 268–270, 270*t*  
 neuroretinitis, 274  
 solar retinitis, 412–413, 413*f*  
 white dot syndromes, 250–260. *See also* White dot syndromes
- Retinitis pigmentosa (RP; rod-cone dystrophies)  
 clinical findings, 179, 291–293, 292–295*f*  
 cystoid macular edema etiology, 176, 178  
 differential diagnosis, 178, 285, 287, 297, 310, 324, 334  
 electrophysiologic findings, 47, 48*f*, 53, 54  
 electroretinography evaluations, 45–47, 46*f*, 52  
 gene therapy for, 458  
 management, 294–295  
 sector retinitis pigmentosa, 47, 291–293, 295*f*  
 systemic disease association, 219, 318, 319, 330  
 X-linked, 53, 291, 456, 456*t*, 458
- Retinitis pigmentosa sine pigmento, 291, 318
- Retinitis punctata albescens, 287, 287*f*
- Retinitis sclopetaria, 401*f*
- Retinopathy. *See also* Chorioretinopathy; Diabetic retinopathy; Pigmentary retinopathy; Retinopathy of prematurity; Sickle cell retinopathy  
 ABCA4 retinopathy, 47–48, 50*f*  
 acute macular neuroretinopathy, 250, 257–259, 259*f*  
 cancer-associated, 322–323, 323*f*  
 drug-induced, 342–343, 344–346, 345–346*f*, 346*t*  
 familial exudative vitreoretinopathy, 179, 360, 362–363, 362*t*  
 hypertensive retinopathy, 132–133, 132–133*f*  
 hyperviscosity retinopathy, 150  
 Purtscher and Purtscher-like retinopathy, 190*t*, 191–192, 191*f*  
 radiation retinopathy, 179, 187–189, 188*f*  
 Valsalva retinopathy, 189–190, 189*f*  
 venous stasis retinopathy, 153
- Retinopathy of prematurity (ROP), 193–213  
 about, 193  
 associated conditions, 209–210  
 classification, 194, 195–200*f*, 195*t*  
 clinical findings, 362*t*

- differential diagnosis, 179, 360, 362, 362*t*
- etiology and epidemiology, 193–194, 362*t*
- fundus photographic screening, 203
- management, 204, 205–206*t*, 207–209
- medicolegal aspects of, 211–213
- pathogenesis, 199–201
- prevention, 203–204
- screening recommendations, 201–203
- sequelae of, 210, 210–212*f*
- terminology, 194–199, 199*t*
- Retinopexy, 422–423, 423*f*, 447–448, 447*f*
- Retinoschisin, 313
- Retinoschisis
  - differential diagnosis, 382, 389–392, 390–391*f*, 391*t*
  - gene therapy for, 456*t*
  - X-linked, 49*f*, 53, 178, 310–313, 312*f*, 328–329, 365
- RetNet, 288
- Retrobulbar tumor, 134
- Retrorenal fibroplasia, 193. *See also* Retinopathy of prematurity
- RGS9 gene, 53
- RH. *See* Retinal hemangioblastomas
- Rhegmatogenous inferior bulbous detachment, 389
- Rhegmatogenous retinal detachment (RRD)
  - chronic, 387, 387*f*
  - diabetic retinopathy treatment complication, 115
  - diagnostic features, 371, 382, 383*t*, 384–386*f*, 387*t*
  - differential diagnosis, 391–392, 391*f*, 391*t*
  - etiology and epidemiology, 382, 394, 394*f*
  - familial exudative vitreoretinopathy association, 362
  - management, 119, 175, 385–387, 445–451, 446–449*f*
  - retinopathy of prematurity association, 210, 210*f*
  - scatter photocoagulation complication, 175
  - terminology, 381–382
  - vision loss caused by, 146
- Rhodopsin kinase, 287, 294
- RIDE and RISE (studies), 100, 124
- Rifabutin, 347
- Rituximab, 265
- RLBP1* gene, 287
- RMC. *See* Recurrent multifocal choroiditis
- Rod–cone dystrophies. *See* Retinitis pigmentosa
- Rod monochromatism, 284–285
- Rod(s)
  - age-related changes, 67
  - anatomy, 11–13, 12*f*
  - density and distribution of, 9–11
  - electro-oculography evaluations, 54
  - electroretinography testing, 45–47, 46*f*
  - night vision abnormalities and, 285–288, 286–288*f*
  - psychophysical evaluations, 61
  - shedding by, 16–17
- ROP. *See* Retinopathy of prematurity
- “ROP safety net,” 213
- Rosiglitazone, 343
- RP. *See* Retinitis pigmentosa
- RP1L1* gene, 310
- RPE. *See* Retinal pigment epithelium
- RPE65* gene, 297, 457–458
- RRD. *See* Rhegmatogenous retinal detachment
- RS1* gene, 312*f*, 313
- Rubeosis iridis, 154
- Rush disease, 195*t*, 196
- RVO. *See* Retinal venous occlusion
- SAG gene, 287
- Salmon-patch hemorrhage, 168, 170*f*
- Sanfilippo syndrome, 316*t*, 327
- Sarcoidosis, 250, 253, 262, 367
- Sattler layer, 18
- Scanning laser ophthalmoscopy (SLO), 24–26, 25*f*, 30–32, 31*f*
- Scatter photocoagulation, 147–148, 175. *See also* Photocoagulation
- Scheie syndrome, 316*t*, 327
- Schisis. *See also* X-linked retinoschisis
  - bullous retinoschisis, 310, 312*f*, 390, 390*f*
  - foveal, 312*f*
  - macular, 96*f*, 237–238, 238*f*, 297, 298*f*, 312*f*, 391–392, 391*f*
  - of posterior vitreous, 350, 351
  - retinal, 310–313, 312*f*, 382, 389–392, 390–391*f*, 391*t*, 456*t*
  - trauma-related, 411
- Schlaegel lines, 256, 256*f*
- Sclera
  - anatomy, 19
  - choroidal folds and, 230, 230*f*, 231*t*
  - laceration of, 403
  - myopia and, 237*f*, 243–246, 245*f*
  - rupture of, 401–402
  - thickness of/permeability of, 19
- Scleral buckling, 209, 385, 392, 448–449, 448*f*
- Scleral fixation, 442
- Scleral window surgery, 232
- Scleritis, 278
- Sclerotomy, 444–445, 444*f*
- S-cone (blue-cone) monochromatism, 49*f*, 284, 285
- S cones, 57
- SCORE (study), 140–141*t*
- SCORE2 (study), 142*t*, 144
- Scotoma
  - absolute, 391, 391*t*
  - acute macular neuroretinopathy association, 257
  - multifocal choroiditis association, 256
  - multiple evanescent white dot syndrome association, 254
  - paracentral, 77, 95, 127, 259, 412, 413–414
  - retina dystrophies association, 294*f*, 296
  - retinoschisis association, 391, 391*t*
  - rod–cone dystrophies association, 291, 294*f*
  - serpiginous choroidopathy association, 253
  - “Scrambled-egg” macular lesions, 302
- SDH. *See* Shape-discrimination hyperacuity
- SD-OCT. *See* Spectral-domain optical coherence tomography
- Sea-blue histiocyte syndrome, 328
- “Sea fan” pattern, of neovascularization, 77, 82*f*, 168, 171, 173*f*, 175
- Secondary panretinal dystrophies, 290
- Sector retinitis pigmentosa, 47, 291–293, 295*f*
- Segmentation, 437
- Senior-Løken syndrome, 320
- Septic emboli, 156
- Serous pigment epithelial detachment, 79, 80*f*, 81

- Serous retinal detachment. *See* Exudative retinal detachment
- Serpiginous choroidopathy, 251*t*, 252, 253, 254*f*, 272
- Shafer sign (“tobacco dust”), 365, 382
- Shaggy photoreceptors, 218*f*
- Shaken baby syndrome, 411, 411*f*
- Shape-discrimination hyperacuity (SDH), 77
- Sheenlike retinal whitening, 398, 398*f*
- Shimmering, electroretinography findings in, 53
- Shock, fluorescein adverse effect, 37
- Short-wavelength sensitive cones, 57
- Sickle cell anemia, 95
- Sickle cell disease, 167–168, 167*t*, 171, 174, 339*f*. *See also* Sickle cell retinopathy
- Sickle cell–hemoglobin C (HbSC) disease, 168, 173*f*
- Sickle cell retinopathy
- differential diagnosis, 169–171, 174*t*
  - management, 174–175
  - nonproliferative, 168, 169–172*f*
  - other ocular abnormalities, 171–174
  - proliferative, 168–171, 173*f*, 175
  - stages of, 168, 169*f*
- Sickle cell–thalassemia (SThal), 168
- Sickle cell trait (HbAs), 169, 174
- Sickling hemoglobinopathy, 167*t*, 174
- Siderosis bulbi, 407, 407*t*, 408*f*
- Siegrist streaks, 134, 225
- Signal voids, 29
- Sildenafil, 338–339, 347
- Silicone oil, 450, 454
- Silicone Study, 450
- Sjögren-Larsson syndrome, 320, 322*f*
- Skin, fluorescein adverse effects on, 38
- SLE. *See* Systemic lupus erythematosus
- Sleep apnea, 217
- Slit lamp, indirect ophthalmoscopy with, 22–23
- Slit-lamp biomicroscopy, 122
- SLO. *See* Scanning laser ophthalmoscopy
- SMD. *See* Sorsby macular dystrophy
- Smokestack form, 216, 216*f*
- “Snail track” degeneration, 372*f*
- Snellen visual acuity, 59
- Snowbanks, 277
- “Snowflakes,” 390, 390*f*
- Social determinants, 93, 101
- Soft drusen, 67, 67*f*, 69–70, 69*f*, 85, 229*f*, 303
- Soft exudates, 132
- Solar retinitis, 412–413, 413*f*
- Solar retinopathy, 412–413, 413*f*
- Sorsby macular dystrophy (SMD), 306, 307*f*
- Spatial frequency, 59–60
- Spectral-domain optical coherence tomography (SD-OCT), 26–27, 50*f*, 52*f*
- Spinocerebellar degeneration, 316*t*
- Spirolactone, 221
- Spokelike folds, 310, 312*f*
- Spondyloepiphyseal dysplasia congenita, 319*t*
- Sporadic retinal dystrophy, 293
- Stable dyschromatopsias, 283
- Staining hyperfluorescence, 35, 35*t*, 36
- Standing potential, 53, 54*f*
- Staphylococcus* spp, 270, 437–438
- Staphyloma, 96*f*, 237*f*, 238–239, 245, 245*f*, 394
- Stargardt disease, 47–48, 50*f*, 300–302, 301*f*, 456*t*
- “Starry night” sign, 263, 264*f*
- Static dyschromatopsia, 283
- Static nyctalopia, 285
- Stationary dyschromatopsias, 283
- Stationary nyctalopia, 285
- Steinert disease, 316*t*
- Stem cell treatments, 295, 302
- Stereopsis, 22
- Steroid implants, 126
- Steroids. *See* Corticosteroids
- SThal. *See* Sickle cell–thalassemia
- Stickler syndrome, 316*t*, 361, 361*f*, 370, 381
- Strabismus, 209–210
- Streptococcus* spp, 270, 271*f*, 437–438, 441, 453
- Stress, 217
- Striae, of retina, 353
- “String-of-pearls” pattern, 85, 265, 265*f*, 273*f*
- Strokes, 154, 160, 161*f*, 176
- Sturge-Weber syndrome, 181, 231
- Subclinical retinal detachment, 381
- Subfoveal pigment epithelial detachment, 81*f*
- Submacular hemorrhage, 93, 399, 434–435, 434–435*f*
- Subretinal drusenoid deposits, 25
- Subretinal fibrosis, 127, 179, 257, 257*f*
- Subretinal fibrosis and uveitis syndrome, 256
- Subretinal fluid
- age-related changes, 77, 78, 79*f*, 81*f*, 82, 86
  - in central serous chorioretinopathy, 86
  - in pathologic myopia, 96*f*
- Subretinal hemorrhage
- differential diagnosis, 239
  - myopia and, 239
  - photocoagulation complication, 425
  - in polypoidal choroidal vasculopathy, 85, 86
  - trauma-related, 398, 399*f*
  - in Valsalva retinopathy, 190
- Subretinal hyperreflective material (SHRM), 81–82, 81*f*
- Subretinal neovascularization, 180
- Subretinal space, 17
- Sub-Tenon space, 19
- “Sugiura” sign, 263
- Sulfadiazine, 276
- Sulfa drugs, 347
- “Sunburst” lesions, 168
- “Sunflower” cataract, 407
- “Sunset glow” sign, 263
- Superficial vascular plexus, 13, 30*f*
- “Supertraction” or “supertraction crescent,” 239
- Suprachoroidal hemorrhage, 397, 443–445, 444*f*
- Susac syndrome, 176
- SUSTAIN (study), 66, 89
- Swept-source optical coherence tomography (SS-OCT), 26
- Sympathetic ophthalmia, 263, 410
- Synchysis, vitreous, 378
- Synchysis scintillans, 366
- Syndromic panretinal dystrophies, 289–290
- Synechia, 119
- Syneresis, vitreous, 349, 364, 369
- Syphilis, 250, 253, 269, 274
- Syphilitic chorioretinitis, 274, 275*f*

- Syphilitic retinochoroiditis, 274, 275f
- Systemic anticoagulation, 145
- Systemic arterial hypertension ocular diseases, 131–134, 132–133f, 135
- Systemic diseases
- with retinal degeneration
    - autoimmune retinopathies, 323
    - Bardet-Biedl syndrome, 316t, 318–319, 318f
    - Leber congenital amaurosis, 318
    - neuromuscular disorders, 316t, 319
    - organ-specific diseases, 318, 320–322
    - paraneoplastic retinopathies, 322–323, 323f
    - Usher syndrome, 316t, 319, 319t
  - retinal degeneration differential diagnosis
    - albinism, 324–325
    - amino acid disorders, 329
    - central nervous system abnormalities, 316–317t, 325–329, 326–329f
    - mitochondrial disorders, 330, 330–331f
- Systemic drug-induced retinal toxicity
- argyrosis, 347
  - choroidal effusions, 347
  - color vision abnormalities, 347
  - crystalline retinopathy, 344–346, 345–346f, 345t
  - electroretinography abnormalities, 347
  - ganglion cell damage, 343, 344f
  - macular edema, 343–344, 347
  - microvasculopathy, 342–343
  - myopia, 347
  - optic neuropathy, 343
  - retinal pigment epithelium abnormalities
    - chloroquine derivatives, 333–337, 334–336f
    - miscellaneous medications, 337–340, 339f, 340t, 341–342f
    - phenothiazines, 337, 338f
  - retinopathy, 342–343
  - uveitis, 347
- Systemic lupus erythematosus (SLE), 192, 262, 262f
- Tadalafil, 347
- Talc emboli, 156, 346
- Tamoxifen, 334–335, 344–346, 346f
- Taxanes, 178, 343
- Tay-Sachs disease, 328, 328–329f
- Telangiectasia, macular, 86, 180–181, 181–183f, 346
- Telangiectasia, retinal, 178, 179f, 186
- Telemedicine screenings, 201, 203
- TENAYA (study), 98
- Terson syndrome, 192, 192f
- Tessellation, 242
- Tetracycline, 279
- Thalassemia, 167, 167t
- Thermal injuries, 412, 424
- Thermal laser, for neovascular age-related macular degeneration, 87
- Thiazolidinediones, 123
- Thioridazine, 337, 338f
- 3-mirror lens, 23
- Threshold (retinopathy of prematurity), 194, 199t
- Thrombi
  - comma-shaped, 171
  - differential diagnosis, 176
- Thromboembolic events, 125
- Thrombotic thrombocytopenic purpura, 223
- Tick-borne diseases, 278–279
- Tilted disc syndrome, 245, 245f
- Time-domain (TD) optical coherence tomography (OCT), 26
- Time-resolved fluorescence imaging, 32
- TIMP3* gene, 306
- Tissue plasminogen activator (tPA), 161–162
- T lymphocytes, 263
- “Tobacco dust,” 365, 391–392
- “Tomato ketchup fundus,” 231
- Topiramate, 230, 231t, 347
- Toxocara canis*, 277
- Toxocara cati*, 277
- Toxocara* spp, 277, 279
- Toxocariasis, 277–278, 278f, 360
- Toxoplasma gondii*, 269, 274–275
- Toxoplasmic chorioretinitis, 274–277, 277f
- Toxoplasmosis, 309
- tPA. *See* Tissue plasminogen activator
- TP-PA. *See* *Treponema pallidum* particle agglutination assay
- Traction (tractional) retinal detachment (TRD)
  - central nervous system abnormalities and, 321
  - diabetic, 436–437, 436f
  - diabetic retinopathy treatment complication, 115, 120
  - diagnostic features, 383t, 384f, 387–388, 388f
  - management, 119, 120, 436–437, 436f
  - radiation retinopathy complication, 188
  - retinopathy of prematurity association, 193, 201, 210, 211f
  - rod–cone dystrophies association, 294f
  - sickle cell retinopathy association, 168
  - toxocariasis association, 277
- Tractional tufts, 371–372, 373–374f
- Traction foveal detachment, 355
- “Trail of echoes” artifact, 405f
- Trametinib, 341f
- Transconjunctival cryopexy, 448
- Transient hypotony, 444
- Transmission (window) defect hyperfluorescence, 35, 35t, 36, 255
- Transpupillary thermotherapy (TTT), 425
- 11-*trans*-retinaldehyde, 17
- Transscleral cryotherapy, 445, 448
- Transthyretin mutation, 366, 366f
- Trauma
  - pediatric, 377–379
  - pigment granule finding, 365
  - Purtscher and Purtscher-like retinopathy and, 190–192, 190t, 191–192f
  - retinal break cause, 376–377
  - sympathetic ophthalmia and, 263
  - Terson syndrome and, 192f
- Traumatic hyphema, 174–175
- TREND (study), 66, 90
- Treponema pallidum* particle agglutination assay (TP-PA), 274
- Triamcinolone, 350, 352f
- Triamcinolone acetonide, 112t, 124, 125f, 126, 145
- Trichromacy, 283
- Trichromatism, 283, 284t
- Trimethoprim-sulfamethoxazole, 276

- Tritan, 284  
 Tritan axis errors, 59  
 TTT. *See* Transpupillary thermotherapy  
 Tubercular serpiginous-like choroiditis, 253  
 Tuberculosis, 250, 253, 272–273, 273f  
 Tumor necrosis factor inhibitors, 261  
 Tunica vasculosa lentis, 207, 358, 359f  
 Type 1 diabetes, 100, 101, 103, 104t  
 Type 2 diabetes, 100, 101, 103, 104t, 108  
 Typical degenerative retinoschisis, 389, 390, 391  
 Typical peripheral cystoid degeneration, 375–376, 389
- UBM. *See* Ultrasound biomicroscopy  
 UKPDS (study), 100, 104–105, 106t, 108  
 Ultrasonography (B-scan), 26, 27f, 39–41, 40–41f, 397  
 Ultrasound biomicroscopy (UBM), 41  
 Umbo, 7f, 8, 8t  
 Urticarial reactions, 37  
 USH2A gene, 292f, 294f  
 Usher syndrome, 290, 316t, 319, 319t, 456t  
 Uveal effusion syndrome, 231–232, 233f  
 Uveal lymphoma, 265–266, 266f  
 Uveitis
  - Behçet disease association, 261
  - cystoid macular edema etiology, 176
  - differential diagnosis, 264–267, 291
  - drug-induced, 347
  - electroretinography findings, 47
  - imaging techniques, 34f, 39
  - immune recovery, 268
  - intermediate, 277
  - Lyme disease association, 278
  - Mycobacterium tuberculosis*, 272
  - panuveitis, 39, 95, 261, 263, 274, 277, 281
  - syphilitic, 274
  - in toxocariasis, 277
  - Vogt-Koyanagi-Harada disease association, 263
- Valacyclovir, 270t  
 Valganciclovir, 267–268, 270t  
 Valsalva retinopathy, 189–190, 189f  
 Vancomycin, 342, 438, 438t  
 Variable expressivity, 288  
 Varicella-zoster virus (VZV), 268, 269, 269f, 270t  
 Vascular endothelial growth factor (VEGF), 87, 135, 137, 200–201. *See also* Antiangiogenic therapies  
 Vascular filling defects, in fluorescein angiography, 34f, 35  
 Vascularized serous pigmented epithelial detachment (PED), 79, 80f  
 Vascular leakage, 29  
 Vasculitis
  - differential diagnosis, 176
  - inflammatory, 259f, 260, 262, 262f
  - lupus, 262, 262f
  - retinal, 175–176, 175f
- Vasculogenesis, 193, 194  
 Vasoproliferative tumor (VPT), 179, 185  
 VECs. *See* Visual evoked cortical potentials  
 Vector delivery systems, 455, 457, 458  
 VEGF. *See* Vascular endothelial growth factor  
 VEGFR1 gene, 90  
 VEGFR2 gene, 90  
 VEGF Trap. *See* Aflibercept
- VEGF Trap-Eye, 144  
 Venous beading, 108–109, 109f  
 Venous stasis retinopathy, 153  
 VEPs. *See* Visual evoked potentials  
 VER. *See* Visual evoked response  
 Vernier acuity, 76–77  
 Verteporfin, 85, 87, 184, 221, 426. *See also* Photodynamic therapy  
 Vestibular areflexia, 319  
 VHL. *See* Von Hippel–Lindau syndrome  
 VIBRANT (study), 142t, 144  
 VIEW 1 (study), 66, 89t, 90  
 VIEW 2 (study), 66, 89t, 90  
 Vigabatrin, 347  
 VISION (study), 88f  
 Vision loss
  - in birdshot chorioretinopathy, 256
  - diabetic-related, 99, 101, 102, 104, 109–110, 121–122
  - in diffuse unilateral subacute neuroretinitis, 279
  - drug-induced, 111, 334, 342, 343, 345, 347
  - electrophysiologic evaluations, 55, 56
  - in endophthalmitis, 272
  - pregnancy-related, 104
  - in retinal dystrophies, 290–291
  - in toxocariasis, 277–278
  - in toxoplasmic chorioretinitis, 274–275
  - in vascular occlusive diseases, 145–146, 159
  - in vitreomacular traction syndrome, 355
- VISTA (study), 100, 124  
 Visual acuity
  - antiangiogenic therapies for, 88–91, 88f, 89t, 92t, 96–97
  - testing for, 57
- Visual evoked cortical potentials (VECPs), 55  
 Visual evoked potentials (VEPs), 44t, 51, 55–56, 56f, 324  
 Visual evoked response (VER), 55  
 Visual field testing, 57  
 Vitamin A deficiency, 292, 294, 326  
 Vitamin A supplementation, 294, 326  
 Vitamin B<sub>6</sub> supplementation, 300  
 Vitamin C supplementation, 75, 76t  
 Vitamin E supplementation, 75, 76t  
 Vitelliform (egg yolk–like) macular lesion, 302–303, 302f  
 Vitelliform exudative macular detachment, 303, 305f  
 Vitelliform lesions, 302–305, 302f, 304–305f  
 Vitelliform macular dystrophy, 32, 54  
 Vitiliginous chorioretinitis, 265, 266  
 Vitiligo, 263, 264f  
 Vitrectomy. *See also* Pars plana vitrectomy
  - amyloidosis treatment, 366f, 367
  - anterior segment surgery complication management, 437–445, 438t, 439–440f, 441t
  - asteroid hyalosis treatment, 365
  - cystoid macular edema treatment, 178, 443, 443f
  - diabetic macular edema treatment, 127, 128
  - diabetic retinopathy complication management, 435–437, 436f
  - diabetic retinopathy treatment, 116, 119, 120
  - endophthalmitis treatment, 272, 273f
  - macular epiretinal membrane treatment, 431–432, 431–432f

- needle injuries, 445
- open-globe injury repair, 403–404
- persistent fetal vasculature treatment, 360
- posterior dislocated intraocular lens management, 442–443
- posterior vitreous detachment treatment, 349, 350, 352*f*
- retinal detachment treatment, 392
- retinopathy of prematurity treatment, 209
- submacular hemorrhage treatment, 434–435, 434–435*f*
- suprachoroidal hemorrhage treatment, 443–445, 444*f*
- Terson syndrome treatment, 192
- vitreomacular traction disease treatment, 432–433*f*, 432–434
- vitreous opacity treatment, 435
- Vitreomacular adhesions, 354, 354*t*
- Vitreomacular traction, 354, 354*t*
- Vitreomacular traction diseases, 432–434, 432–433*f*
- Vitreomacular traction (VMT) syndrome, 350, 351*f*, 354–355, 354*t*, 355*f*, 432, 432*f*
- Vitreoretinal adhesions, 351, 355
- Vitreoretinal lymphoma, 255
- Vitreoretinal surgery, 115, 120, 175
- Vitreoretinal tufts, 371–372, 373*f*
- Vitreous
  - age-related changes in, 349
  - anatomy, 5–7, 6*f*, 349, 369
  - avulsion of base, 370*f*, 377, 398
  - developmental abnormalities, 358–361, 359*f*
  - imaging techniques, 26, 28*f*, 40–41, 41*f*
  - inflammation, 94–95
  - liquefaction of, 378
  - opacities, 364–367, 364*f*, 366*f*, 429, 435
  - syneresis of, 349, 364, 369
  - traction, myopia and, 237
- Vitreous detachment
  - opacities association, 364
  - posterior, 349–358, 369–371. *See also* Posterior vitreous detachment
- Vitreous hemorrhage
  - in central retinal vein occlusion, 145, 148
  - in diabetic retinopathy, 114, 114*f*, 120
  - differential diagnosis, 367
  - electroretinography testing, 47
  - etiology and epidemiology, 365
  - in macular dystrophy, 310, 311
  - management, 115, 117, 119, 120, 371, 380, 436
  - photocoagulation complication, 425
  - in polypoidal choroidal vasculopathy, 85
  - in posterior vitreous detachment, 370–371
  - in retinal detachment, 391–392
  - in retinal venous occlusion, 145, 148
  - in sickle cell retinopathy, 168
  - in Terson syndrome, 192, 192*f*
  - trauma-related, 397, 400–401, 411
  - in Valsalva retinopathy, 189–190
- Vitreous needle tap, 438
- Vitreous opacities, 364–367, 364*f*, 366*f*, 429, 435
- “Vitreous veils,” 310, 312*f*
- VIVID (study), 100, 124
- VKH disease. *See* Vogt-Koyanagi-Harada disease
- VMD2 gene, 303
- VMT. *See* Vitreomacular traction syndrome
- Vogt-Koyanagi-Harada (VKH) disease (syndrome), 263, 264*f*
- Vogt ring, 350
- Volume scans and rendering, 26, 27–28, 27*f*
- Von Hippel lesions, 185
- Von Hippel–Lindau (VHL) syndrome, 179, 181–185, 184–185*f*
- Voretigene neparvec-rzyl, 455, 457–458
- Voriconazole, 271, 272, 438*t*
- Vortex veins, in choroid, 18
- VPT. *See* Vasoproliferative tumor
- VZV. *See* Varicella-zoster virus
- Waardenburg syndrome, 316*t*
- Wagner hereditary vitreoretinal degeneration, 316*t*
- Wagner syndrome, 361
- Wandering nystagmus, 296
- Wegener granulomatosis. *See* Granulomatosis with polyangiitis
- Weill–Marchesani syndrome, 361
- Weiss ring, 350, 350*f*, 357
- WESDR (study), 100, 101
- West Nile virus chorioretinitis, 279, 280*f*
- “Wet” age-related macular degeneration (AMD), 67.
  - See also* Neovascular age-related macular degeneration
- Whiplash injuries, 399–400
- Whipple disease, 367
- White dot syndromes, 250–260
  - about, 250, 251*t*
  - acute idiopathic maculopathy, 250, 259–260, 260*f*
  - acute macular neuroretinopathy, 250, 257–259, 259*f*
  - acute posterior multifocal placoid pigment epitheliopathy, 250–252, 251*t*, 252*f*, 253
  - acute zonal occult outer retinopathy, 250, 251*t*, 257, 258*f*
  - birdshot chorioretinopathy, 39, 53, 251*t*, 255–256, 255*f*
  - multifocal choroiditis, 250, 251*t*, 256–257, 256–257*f*
  - multiple evanescent white dot syndrome, 251*t*, 254–255, 254*f*
  - serpiginous choroidopathy, 251*t*, 253, 254*f*
- White infarct, 165
- Whorls, 329
- Wide-field contact lenses, 23
- Wieger ligament, 5, 6*f*
- Wilson disease, 407
- Window (transmission) defect hyperfluorescence, 35, 35*t*, 36, 255
- Wine birthmark (ipsilateral facial nevus flammeus), 231
- WINROP algorithm, 202
- Wrinkling, of retina, 353
- Wyburn-Mason syndrome, 186, 186*f*
- Xanthocoria, 178
- Xanthophyll, 419–421, 420*f*
- Xanthopsia, 347
- X-linked disorders. *See also* X-linked retinoschisis
  - color vision dysfunction, 57, 284
  - cone dystrophy, 288*f*

- congenital stationary night blindness, 285–286, 286*f*
- familial exudative vitreoretinopathy, 179, 360, 362–363, 362*t*
- incontinentia pigmenti, 317*t*, 320–321
- mucopolysaccharidoses, 316*t*, 317*t*, 327
- ocular albinism, 324
- Pelizaeus-Merzbacher disease, 317*t*
- retinitis pigmentosa, 53, 291, 456*t*, 458
- X-linked retinoschisis (XLRS)
  - about, 310–313, 312*f*
  - differential diagnosis, 178, 365
  - electroretinography findings, 49*f*, 53
  - with retinal degeneration, 328–329
- YAG vitreolysis, 435
- Yeast endophthalmitis, 272, 273*f*
- Zeaxanthin, 75–76, 76*t*, 412
- Zellweger spectrum disorders (cerebrohepatorenal syndrome), 317*t*, 326–327, 327*f*
- Zika virus chorioretinitis, 279–281
- Zinc
  - age-related macular degeneration management, 75, 76, 76*t*
  - as foreign body, 406
- Zonulae occludentes, 15
- Zonular traction retinal tufts, 371–372, 373*f*

